

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

APPLICATION ELEMENTS

See MPEP Chapter 600 concerning utility patent application contents.

 ADDRESS TO: Assistant Commissioner for Patents
 Box Patent Application
 Washington, D.C. 20231

1. [X] * Fee Transmittal Form (e.g., PTO/SB/17)

(Submit an original, and a duplicate for fee processing)

2. [X] Specification Total Pages [88]

(preferred arrangement set forth below)

- Descriptive Title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R&D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3. [X] Drawing(s) (35 USC 113) Total Sheets [15]

4. Oath or Declaration Total pages [2]

- a. ☐ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 16 completed)

i. ☐ DELETION OF INVENTORSSigned statement attached deleting inventor(s)
named in the prior application, see 37 CFR
§§1.63(d)(2) and 1.33(b).

**NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY
SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS
REQUIRED (37 C.F.R. §1.27), EXCEPT IF ONE FILED IN A PRIOR
APPLICATION IS RELIED UPON (37 C.F.R. §1.28).**

16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in the preliminary amendment:

☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application Nos. 60/091,076, 09/107,561,
09/106,225, 60/090,993 and 08/970,508
Prior application information: Examiner: Not Assigned, C. Coquit, M.C. Peppers, III, Not Assigned and D. Ruhl, respectively.Group/Art Unit: Not Assigned, 3761, 3761, Not Assigned and 3761, respectively.

For CONTINUATION or DIVISIONAL only. The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation may only be relied upon when a portion has been independently created from the submitted application parts.

17. CORRESPONDENCE ADDRESS

[] Customer Number or Bar Code Label

(Insert Customer No. or Attach bar code label here)

or [] Correspondence address below

NAME	Kevin D. Hogg			
	The Procter & Gamble Company			
ADDRESS	Winton Hill Technical Center			
	6300 Center Hill Avenue			
CITY	Cincinnati	STATE	Ohio	ZIP CODE 45224
COUNTRY	USA	TELEPHONE	(513) 634-1331	FAX (513) 634-6174

Name (Print/Type)	Kevin D. Hogg	Registration No. (Attorney/Agent)	31,839
Signature		Date	6/29/99

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

06/29/99

3572 U.S. PTO

Attorney Docket No.	7590Q
First Inventor or Application Identifier	DONALD C. ROE, ET AL
Title	DISPOSABLE ARTICLE PROVIDING IMPROVED MANAGEMENT OF BODILY EXUDATES
Express Mail Label No.	EJ312913649US

 +
 06/29/99
 3572 U.S. PTO

"Express Mail" mailing label number EJ312913649/8

Date of Deposit June 29, 1999

I hereby certify that this paper/fe is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.19 on the date indicated above and is addressed to The Assistant Commissioner for Patents, Washington, D.C. 20231.

David M. Wiersch 38,361
Attorney mailing application Reg. No.

Signature of Attorney mailing application

CASE 7590Q

DISPOSABLE ARTICLE PROVIDING
IMPROVED MANAGEMENT OF BODILY EXUDATES

DONALD C. ROE
NICHOLAS A. AHR
CHRISTOPHER P. BEWICK-SONNTAG
MATTIAS SCHMIDT
OLIVER E.C. MASON
STEPHEN A. GOLDMAN

FIELD OF THE INVENTION

The present invention relates to disposable articles which receive (i.e., which absorb and/or contain) bodily exudates, including disposable absorbent articles such as diapers, adult incontinence products, sanitary napkins, disposable bodily waste-receiving articles such as waste or colostomy bags, and the like. More particularly, the invention relates to disposable articles which provide improved management of bodily exudates by including one or more agents which act to modify the physical properties of feces or other bodily wastes which may be deposited in the article, or by including one or more compositions such as the aforesaid agents which enhance the removability of bodily waste, such as feces, from the skin of the article's wearer.

BACKGROUND OF THE INVENTION

The major function of absorbent articles such as diapers, adult incontinence briefs, sanitary napkins and other disposable articles for receiving body exudates is to prevent such body exudates from soiling, wetting, or otherwise contaminating clothing or other articles, such as bedding, that may come in contact with the wearer. In recent years, disposable diapers, such as those disclosed in U.S. Pat. No. 5,151,092 issued to Buell et al., have become very popular and have generally replaced durable cloth absorbent articles because of their convenience and reliability. However, despite the effectiveness of such disposable absorbent articles, body exudates often still leak or are stored in the article such that the exudates soil and/or irritate the skin of the wearer. Additionally, body exudates often adhere aggressively to skin, increasing the difficulty of cleaning and increasing the likelihood of chronic residual contamination. The fundamental causes of these, and other key problems with absorbent articles of the art lie in the mobility under applied shear stress and adhesiveness of the feces.

The undesirable effects of leakage and/or improper containment, difficult cleanup, and/or residual skin contamination are especially evident with regard to fecal matter deposited in the article. Feces contained in the article which comes in contact with the wearer, or which is left on the skin after attempts at cleanup, can harm the skin of the wearer over time. Feces leaking from the article almost invariably presents unpleasant, messy cleanups of not only the wearer, but also of clothing or other objects that may come in contact with the wearer. Thus, several attempts have been made to add features to absorbent articles such as barriers, pockets, spacers, transverse barriers, apertured topsheets and the like to limit the movement of the fecal material across the topsheet and/or to better confine the fecal matter in the article. However, such attempts have been generally unsuccessful because they fail to address the fundamental causes of these problems (i.e., the properties of feces) and, because of their cost and complexity. Further, many of the means for isolating or containing feces are directed to fecal material with certain physical properties (e.g., viscosity, free water content and particle size) and are not effective with exudates with physical properties outside a very small range.

U.S. Patent 4,790,836 discloses a diaper including layer of medicated powder located between the absorbent core and a water-soluble film. The medicated powder is used to promote drying of the infant's skin after the wearer wets the diaper. However, as shown in Tables II and VIII, below, embodiments such as disclosed in this patent do not function to provide the feces management benefits of the present invention. It is also known to coat a topsheet of a disposable absorbent article with a lotion composition which can transfer to the skin of the wearer, such as disclosed in U.S. Pat. Nos. 5,607,760, 5,609,587, 5,635,191 and 5,643,588. However, such a lotion composition alone may not provide the enhanced fecal removability/cleaning benefit of the present invention.

Accordingly, it would be desirable to provide a disposable article with improved bodily exudate management properties, such as a disposable article providing desirable feces modification and/or enhanced feces removability. Further, it would be advantageous to provide an economical disposable article with the ability to minimize the negative effects of feces or other viscous bodily waste on the wearer or the caregiver. It would also be advantageous to provide an article which is designed to chemically or physically interact with the feces and to change the properties of the feces in order to improve acceptance of feces into the article and/or immobilization of the feces within the article and/or reduce the residual contamination of the wearer's skin with feces. Also, it would be desirable to provide an article having sufficient effective capacity and retention capability to store the physically or chemically modified feces safely and cleanly away from the wearer's skin and/or clothing throughout the expected time of use. It would be further desirable to provide an article which enhances the efficacious cleanup of feces from the wearer's skin.

SUMMARY OF THE INVENTION

In order to help resolve at least some of the problems described above and otherwise found in the absorbent articles of the prior art, the present invention provides an article which provides improved management of bodily exudates by including an agent which is available in an effective concentration to physically or

chemically modify some or all of the fecal material or other bodily exudates deposited in the article or on the wearer's skin, or which includes one or more compositions, such as a feces modifying agent, for enhancing the removability and cleanup of feces or other bodily exudates from the wearer's skin. The modification of the feces may improve acceptance and/or retention of the exudates within the article to reduce the spreading of fecal material within the diaper and/or to reduce the tendency of the fecal material to adhere to the wearer's skin. The present invention may also provide an absorbent article capable of accepting, storing and/or immobilizing the exudates in their modified form to reduce the likelihood that the waste will migrate back toward the wearer's skin once the waste is imbibed by the article. Accordingly, the absorbent article of the present invention may reduce the likelihood of harm to the wearer's skin and/or the inconvenience to the caregiver normally associated with bowel movements or the excretion of other body exudates.

BRIEF DESCRIPTION OF THE DRAWINGS

While the specification concludes with claims particularly pointing out and distinctly claiming the subject matter which is regarded as the present invention, it is believed that the description will be better understood from the following descriptions which are taken in conjunction with the accompanying drawings in which like designations are used to designate substantially identical elements.

Figure 1 is a plan view of an absorbent article embodiment of the present invention having portions cut away to reveal the underlying structure, the body-facing surface of the diaper facing the viewer.

Figure 2 is a plan view of an absorbent article embodiment of the present invention having portions cut away to reveal the underlying structure, the body-facing surface of the diaper facing the viewer.

Figure 3 is a cross sectional view of an absorbent article embodiment of the present invention taken through the section lines 3-3.

Figure 4 is a cross sectional view of an alternative embodiment of an absorbent article of the present invention.

Figure 5 is a plan view of a sanitary napkin embodiment of the present invention with portions cut away to review the underlying structure.

Figure 6 is a plan view of an alternative embodiment of the present invention.

Figure 7 is an enlarged cross sectional view of an embodiment of the present invention.

Figure 8 is a plan view of an absorbent article embodiment of the present invention having portions cut away to reveal the underlying structure, the body-facing surface of the diaper facing the viewer.

Figure 9 is a schematic front view of an apparatus which may be used to measure Acceptance Under Pressure characteristics of certain structures.

Figure 10 is a plan view of a piece of the apparatus shown in Figure 9.

Figure 11 is a plan view of an absorbent article embodiment of the present invention having portions cut away to reveal the underlying structure, the body-facing surface of the diaper facing the viewer.

Figure 12 is a cross sectional view of a portion of an absorbent article embodiment of the present invention taken through the section lines 12-12 of Figure 11, having additional portions of the article removed.

Figure 13 is a plan view of an assembly which may be used in measuring Waste Contamination Area and Waste Contamination Mass characteristics.

Figure 14 is a plan view of an assembly and apparatus which may be used in measuring Waste Contamination Area and Waste Contamination Mass characteristics.

Figure 15 is a plan view of an assembly and apparatus which may be used in measuring Waste Contamination Area and Waste Contamination Mass characteristics.

Figure 16 is a plan view of an assembly and apparatus which may be used in measuring Waste Contamination Area and Waste Contamination Mass characteristics.

Figure 17 is a plan view of an apparatus which may be used in measuring Waste Contamination Area and Waste Contamination Mass characteristics.

Figure 18 is a side view of an apparatus which may be used in measuring Waste Contamination Area and Waste Contamination Mass characteristics.

Figure 19 is a perspective view of an assembly and apparatus which may be used in measuring Waste Contamination Area and Waste Contamination Mass characteristics.

Figure 20 is a plan view of an assembly and apparatus which may be used in measuring Waste Contamination Area and Waste Contamination Mass characteristics.

Figure 21 is a perspective view of a waste bag embodiment of the present invention.

Figure 22 is a perspective view of an absorbent article including a waste bag.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the term "absorbent article" refers to devices which absorb and contain body exudates, and more specifically, refers to devices which are placed against or in proximity to the body of the wearer to absorb and contain the various exudates discharged from the body. The term "disposable" is used herein to describe articles which generally are not intended to be laundered or otherwise restored or reused (i.e., they are intended to be discarded after a single use and, preferably, to be recycled, composted or otherwise disposed of in an environmentally compatible manner). (As used herein, the term "disposed" is used to mean that an element(s) of the diaper is formed (joined or positioned) in a particular place or position as a unitary structure with other elements of the diaper or as a separate element joined to another element of the diaper. As used herein, the term "joined" encompasses configurations whereby an element is directly secured to another element by affixing the element directly to the other element, and configurations whereby an element is indirectly secured to another element by affixing the element to intermediate member(s) which in turn are affixed to the other element.) A "unitary" absorbent article refers to absorbent articles which are formed of separate parts united together to form a coordinated entity so that they do not require separate manipulative parts like a separate holder and liner.

A preferred embodiment of an absorbent article of the present invention is the unitary disposable absorbent article, diaper 20, shown in Figure 1. (As used herein, the term "diaper" refers to an absorbent article generally worn by infants and incontinent persons about the lower torso.) However, the present invention is also applicable to other absorbent articles such as incontinence briefs, incontinence undergarments, inserts including absorbent inserts, diaper holders and liners, feminine hygiene garments, wipes, mops, bandages and the like. The present invention is also applicable to absorbent or nonabsorbent feces collection devices, such as waste or colostomy bags, which may for example be separately applied to the wearer's perianal region.

Figure 1 is a plan view of a diaper 20 of the present invention in a flat-out, state with portions of the structure being cut-away to more clearly show the construction of the diaper 20. The portion of the diaper 20 which faces the wearer is oriented towards the viewer. As shown in Figure 1, the diaper 20 preferably comprises a liquid pervious topsheet 24; a liquid impervious backsheet 26; an absorbent core 28, which is preferably positioned between at least a portion of the topsheet 24 and the backsheet 26; side panels 30; elasticized leg cuffs 32; an elastic waist feature 34; and a fastening system generally designated 40. Diaper 20 is shown in Figure 1 to have a first waist region 36, a second waist region 38 opposed to the first waist region 36 and a crotch region 37 located between the first waist region and the second waist region. The periphery of the diaper 20 is defined by the outer edges of the diaper 20 in which the longitudinal edges 50 run generally parallel to the longitudinal centerline 100 of the diaper 20 and the end edges 52 run between the longitudinal edges 50 generally parallel to the lateral centerline 110 of the diaper 20.

The chassis 22 of the diaper 20 comprises the main body of the diaper 20. The chassis 22 comprises at least a portion of the absorbent core 28 and preferably an outer covering layer including the topsheet 24 and the backsheet 26. If the absorbent article comprises a separate holder and a liner, the chassis 22 generally comprises the holder and the liner. (For example, the holder may comprise one or more layers of material to form the outer cover of the article and the liner may comprise an absorbent assembly including a topsheet, a backsheet, and an absorbent core. In such

cases, the holder and/or the liner may include a fastening element which is used to hold the liner in place throughout the time of use.) For unitary absorbent articles, the chassis 22 comprises the main structure of the diaper with other features added to form the composite diaper structure.

5 While the topsheet 24, the backsheet 26, and the absorbent core 26 may be assembled in a variety of well known configurations, preferred diaper configurations are described generally in U.S. Pat. No. 3,860,003 entitled "Contractible Side Portions for Disposable Diaper" which issued to Kenneth B. Buell on January 14, 1975; U.S. Pat. No. 5,151,092 issued to Buell on September 9, 1992;
10 and U.S. Pat. No. 5,221,274 issued to Buell on June 22, 1993; and U.S. Pat. No. 5,554,145 entitled "Absorbent Article With Multiple Zone Structural Elastic-Like Film Web Extensible Waist Feature" which issued to Roe et al. on September 10, 1996; U.S. Pat. No. 5,569,234 entitled "Disposable Pull-On Pant" which issued to Buell et al. on October 29, 1996; and U.S. Pat. No. 5,580,411
15 entitled "Zero Scrap Method For Manufacturing Side Panels For Absorbent Articles" which issued to Nease et al. on December 3; each of which is incorporated herein by reference.

The backsheet 26 is generally that portion of the diaper 20 positioned adjacent the garment facing surface 45 of the absorbent core 28 which prevents the exudates absorbed and contained therein from soiling articles which may contact the
20 diaper 20, such as bedsheets and undergarments. In preferred embodiments, the backsheet 26 is impervious to liquids (e.g., urine) and comprises a thin plastic film such as a thermoplastic film having a thickness of about 0.012 mm (0.5 mil) to about 0.051 mm (2.0 mils). Suitable backsheet films include those manufactured by
25 Tredegar Industries Inc. of Terre Haute, IN and sold under the trade names X15306, X10962 and X10964. Other suitable backsheet materials may include breathable materials which permit vapors to escape from the diaper 20 while still preventing exudates from passing through the backsheet 26. Exemplary breathable materials may include materials such as woven webs, nonwoven webs, composite materials
30 such as film-coated nonwoven webs, microporous films such as manufactured by Mitsui Toatsu Co., of Japan under the designation ESPOIR NO and by Exxon

Chemical Co., of Bay City, TX, under the designation EXXAIRE, and monolithic films such as manufactured by Clopay Corporation, Cincinnati, OH under the name HYTREL blend P18-3097. Some breathable composite materials are described in greater detail in PCT Application No. WO 95/16746, published on June 22, 1995 in the name of E. I. DuPont, U.S. Pat. No. 5,865,823 issued on February 2, 1999 in the name of Curro, and U.S. Pat. No. 5,571,096 issued to Dobrin et al. on November 5, 1996. Each of these references is hereby incorporated by reference herein.

The backsheets 26, or any portion thereof, may be elastically extensible in one or more directions. In one embodiment, the backsheet 26 may comprise a structural elastic-like film ("SELF") web as described in U.S. Patent No. 5,518,801 entitled Web Materials Exhibiting Elastic-Like Behavior, which issued to Chappell, et al. on May 21, 1996, which is incorporated herein by reference. In alternate embodiments, the backsheet 26 may comprise elastomeric films, foams, strands, or combinations of these or other suitable materials with nonwovens or synthetic films.

The backsheet 26 may be joined to the topsheet 24, the absorbent core 28 or any other element of the diaper 20 by any attachment means known in the art. For example, the attachment means may include a uniform continuous layer of adhesive, a patterned layer of adhesive, or an array of separate lines, spirals, or spots of adhesive. Alternatively, the attachment means may comprise heat bonds, pressure bonds, ultrasonic bonds, dynamic mechanical bonds, or any other suitable attachment means or combinations of these attachment means as are known in the art.

The topsheet 24 is preferably compliant, soft feeling, and non-irritating to the wearer's skin. Further, at least a portion of the topsheet 24 is liquid pervious, permitting liquids to readily penetrate through its thickness. A suitable topsheet 24 may be manufactured from a wide range of materials, such as porous foams; reticulated foams; apertured plastic films; or woven or nonwoven webs of natural fibers (e.g., wood or cotton fibers), synthetic fibers (e.g., polyester or polypropylene fibers), or a combination of natural and synthetic fibers. If the topsheet includes fibers, the fibers may be spunbond, carded, wet-laid, meltblown, hydroentangled, or otherwise processed as is known in the art. One suitable topsheet 24 comprising a

web of staple length polypropylene fibers is manufactured by Veratec, Inc., a Division of International Paper Company, of Walpole, MA under the designation P-8.

Suitable formed film topsheets are described in U.S. Pat. No. 3,929,135, entitled "Absorptive Structures Having Tapered Capillaries", which issued to Thompson on December 30, 1975; U.S. Pat. No. 4,324,246 entitled "Disposable Absorbent Article Having A Stain Resistant Topsheet", which issued to Mullane, et al. on April 13, 1982; U.S. Patent 4,342,314 entitled "Resilient Plastic Web Exhibiting Fiber-Like Properties", which issued to Radel, et al. on August 3, 1982; U.S. Pat. No. 4,463,045 entitled "Macroscopically Expanded Three-Dimensional Plastic Web Exhibiting Non-Glossy Visible Surface and Cloth-Like Tactile Impression", which issued to Ahr, et al. on July 31, 1984; and U.S. Pat. No. 5,006,394 "Multilayer Polymeric Film" issued to Baird on April 9, 1991. Other suitable topsheets 30 are made in accordance with U.S. Pat. Nos. 4,609,518 and 4,629,643 which issued to Curro et al. on September 2, 1986 and December 16, 1986, respectively, and both of which are incorporated herein by reference. Such formed films are available from The Procter & Gamble Company of Cincinnati, Ohio as "DRI-WEAVE" and from Tredegar Corporation of Terre Haute, Indiana as "CLIFF-T."

The topsheet 24 may be made of a hydrophobic material or be treated to be hydrophobic in order to isolate the wearer's skin from liquids contained in the absorbent core 28. If the topsheet 24 is made of a hydrophobic material, preferably at least the upper surface of the topsheet 24 is treated to be hydrophilic so that liquids will transfer through the topsheet more rapidly. This diminishes the likelihood that body exudates will flow off the topsheet 24 rather than being drawn through the topsheet 24 and being absorbed by the absorbent core 28. The topsheet 24 can be rendered hydrophilic by treating it with a surfactant or by incorporating a surfactant into the topsheet. Suitable methods for treating the topsheet 24 with a surfactant or incorporating a surfactant in a topsheet are described in U.S. Pat. No. 4,988,344 entitled "Absorbent Articles with Multiple Layer Absorbent Layers" issued to Reising, et al. on Jan. 29, 1991 and U.S. Pat. No. 4,988,345 entitled "Absorbent Articles with Rapid Acquiring Absorbent Cores" issued to Reising on Jan. 29, 1991,

and U.S. Statutory Invention Registration No. H1670, published on July 1, 1997 in the names of Aziz et al. Each of these references is hereby incorporated by reference herein. Alternatively, the topsheet 24 may include an apertured web or film which is hydrophobic. This may be accomplished eliminating the hydrophilizing treatment
5 step from the production process and/or applying a hydrophobic treatment to the topsheet 24, such as a polytetrafluoroethylene compound like SCOTCHGUARD or a hydrophobic lotion composition, as described below. In such embodiments, it is preferred that the apertures be large enough to allow the penetration of aqueous fluids like urine without significant resistance.

Any portion of the topsheet 24 may be coated with a lotion as is known in the art. Examples of suitable lotions include those described in U.S. Pat. Nos. 5,607,760 entitled "Disposable Absorbent Article Having A Lotioned Topsheet Containing an Emollient and a Polyol Polyester Immobilizing Agent" which issued to Roe on March 4, 1997; U.S. Pat. No. 5,609,587 entitled "Diaper Having A Lotion Topsheet
15 Comprising A Liquid Polyol Polyester Emollient And An Immobilizing Agent" which issued to Roe on March 11, 1997; U.S. Pat. No. 5,635,191 entitled "Diaper Having A Lotioned Topsheet Containing A Polysiloxane Emollient" which issued to Roe et al. on June 3, 1997; and U.S. Pat. No. 5,643,588 entitled "Diaper Having A Lotioned Topsheet" which issued to Roe et al. on July 1, 1997. The lotion may function alone
20 or in combination with another agent as the hydrophobizing treatment described above. The topsheet may also include or be treated with antibacterial agents, some examples of which are disclosed in PCT Publication No. WO 95/24173 entitled "Absorbent Articles Containing Antibacterial Agents in the Topsheet For Odor Control" which was published on September 14, 1995 in the name of Theresa Johnson. Further, the topsheet 24, the backsheet 26 or any portion of the topsheet or
25 backsheet may be embossed and/or matte finished to provide a more cloth like appearance.

The topsheet 24 and backsheet 26 may be joined to each other, the absorbent core 28 or any other element of the diaper 20 by any attachment means known in the
30 art. For example, the attachment means may include a uniform continuous layer of adhesive, a patterned layer of adhesive, or an array of separate lines, spirals or spots

of adhesive. Alternatively, the attachment means may comprise heat bonds, pressure bonds, ultrasonic bonds, dynamic mechanical bonds, or any other suitable attachment means of combinations of these attachment means as are known in the art.

The absorbent core 28 may comprise any absorbent material known in the art.

5 The absorbent core 28 may be manufactured in a wide variety of sizes and shapes (e.g., rectangular, hourglass, "T"-shaped, asymmetric, etc.) and may comprise a wide variety of liquid-absorbent materials commonly used in disposable diapers and other absorbent articles such as comminuted wood pulp, which is generally referred to as airfelt. Examples of other suitable absorbent materials include creped cellulose
10 wadding; meltblown polymers, including coform; chemically stiffened, modified or cross-linked cellulosic fibers; tissue, including tissue wraps and tissue laminates; absorbent foams; absorbent sponges; superabsorbent polymers; absorbent gelling materials; or any other known absorbent material or combinations of materials.

The configuration and construction of the absorbent core 28 may also be
15 varied (e.g., the absorbent core(s) or other absorbent structure(s) may have varying caliper zones, a hydrophilic gradient, a superabsorbent gradient, or lower average density and lower average basis weight acquisition zones; or may comprise one or more layers or structures). However, the total absorbent capacity of the absorbent core 28 should be compatible with the design loading and the intended use of the
20 diaper 20.

Exemplary absorbent structures for use as the absorbent core are described in U.S. Patent 4,610,678 entitled "High-Density Absorbent Structures" issued to Weisman et al. on September 9, 1986; U.S. Patent 4,673,402 entitled "Absorbent Articles With Dual-Layered Cores" issued to Weisman et al. on June 16, 1987; U.S.
25 Patent 4,834,735, entitled "High Density Absorbent Members Having Lower Density and Lower Basis Weight Acquisition Zones", issued to Alemany et al. on May 30, 1989; U.S. Patent 4,888,231 entitled "Absorbent Core Having A Dusting Layer" issued to Angstadt on December 19, 1989; U.S. Pat. No. 5,137,537 entitled "Absorbent Structure Containing Individualized, Polycarboxylic Acid Crosslinked
30 Wood Pulp Cellulose Fibers" which issued to Herron et al. on August 11, 1992; U.S. Patent 5,147,345 entitled "High Efficiency Absorbent Articles For Incontinence

Management" issued to Young et al. on September 15, 1992; U.S. Pat. No. 5,342,338 entitled "Disposable Absorbent Article For Low-Viscosity Fecal Material" issued to Roe on August 30, 1994; U.S. Pat. No. 5,260,345 entitled "Absorbent Foam Materials For Aqueous Body Fluids and Absorbent Articles Containing Such Materials" issued to DesMarais et al. on November 9, 1993; U.S. Pat. No. 5,387,207 entitled "Thin-Until-Wet Absorbent Foam Materials For Aqueous Body Fluids And Process For Making Same" issued to Dyer et al. on February 7, 1995; and U.S. Pat. No. 5,625,222 entitled "Absorbent Foam Materials For Aqueous Fluids Made From high Internal Phase Emulsions Having Very High Water-To-Oil Ratios" issued to DesMarais et al. on July 22, 1997. Each of these patents is incorporated herein by reference.

The diaper 20 may also comprise one or more waist features 34 to help provide improved fit and containment. The elastic waist feature 34 may be constructed in a number of different configurations including those described in U.S. Pat. No. 4,515,595 issued to Kievit et al. on May 7, 1985; U.S. Pat. No. 4,710,189 issued to Lash on December 1, 1987; U.S. Pat. No. 5,151,092 issued to Buell on September 9, 1992; and U.S. Pat. No. 5,221,274 issued to Buell on June 22, 1993. Other suitable waist configurations may include waistcap features such as those described in U.S. Pat. No. 5,026,364 issued to Robertson on June 25, 1991 and U.S. Pat. No. 4,816,025 issued to Foreman on March 28, 1989. All of the above mentioned references are incorporated herein by reference.

The diaper 20 may also include a fastening system 40. The fastening system 40 preferably maintains the first waist region 36 and the second waist region 38 in an overlapping configuration so as to provide lateral tensions about the circumference of the diaper 20 to hold the diaper 20 on the wearer. The fastening system 40 preferably comprises tape tabs and/or hook and loop fastening components, although any other known fastening means are generally acceptable. Some exemplary fastening systems are disclosed in U.S. Patent 3,848,594 entitled "Tape Fastening System for Disposable Diaper" issued to Buell on November 19, 1974; U.S. Patent B1 4,662,875 entitled "Absorbent Article" issued to Hirotsu et al. on May 5, 1987; U.S. Patent 4,846,815 entitled "Disposable Diaper Having An Improved Fastening

Device" issued to Scripps on July 11, 1989; U.S. Patent 4,894,060 entitled "Disposable Diaper With Improved Hook Fastener Portion" issued to Nestegard on January 16, 1990; U.S. Patent 4,946,527 entitled "Pressure-Sensitive Adhesive Fastener And Method of Making Same" issued to Battrell on August 7, 1990; and
5 the herein before referenced U.S. Pat. No. 5,151,092 issued to Buell on September 9, 1992; and U.S. Pat. No. 5,221,274 issued to Buell on June 22, 1993. The fastening system may also provide a means for holding the article in a disposal configuration as disclosed in U.S. Pat. No. 4,963,140 issued to Robertson et al. on October 16, 1990. Each of these patents is incorporated herein by reference. Some exemplary hooks are
10 available from Aplix under the trade names 960E and 960D. Exemplary suitable loops are available from 3M under the trade name EBL and from Guilford under the trade designation 18904. In alternative embodiments, opposing sides of the garment may be seamed or welded to form a pant so as to allow the article to be used as a pull-on type diaper, such as a training pant.

15 The diaper 20 may also include side panels 30 constructed and joined to the chassis in any suitable configuration. Examples of diapers with elasticized side panels are disclosed in U.S. Patent 4,857,067, entitled "Disposable Diaper Having Shirred Ears" issued to Wood, et al. on August 15, 1989; U.S. Patent 4,381,781 issued to Sciaraffa, et al. on May 3, 1983; U.S. Patent 4,938,753 issued to Van Gompel, et al.
20 on July 3, 1990; the herein before referenced U.S. Pat. No. 5,151,092 issued to Buell on September 9, 1992; and U.S. Pat. No. 5, 221,274 issued to Buell on June 22, 1993; U.S. Patent No. 5,669,897 issued to LaVon, et al. on September 23, 1997 entitled "Absorbent Articles Providing Sustained Dynamic Fit"; EPO Publication No. WO 95/13775 A1, published May 26, 1995 entitled "Absorbent Article With Multi-
25 Directional Extensible Side Panels;" each of which is incorporated herein by reference.

The diaper 20 preferably further includes leg cuffs 32 to help provide improved containment of liquids and other body exudates. Leg cuffs may also be referred to as leg bands, side flaps, barrier cuffs, or elastic cuffs. U.S. Patent
30 3,860,003 describes a disposable diaper which provides a contractible leg opening having a side flap and one or more elastic members to provide an elasticized leg cuff

(a gasketing cuff). U.S. Patent Nos. 4,808,178 and 4,909,803 issued to Aziz et al. on February 28, 1989 and March 20, 1990, respectively, describe disposable diapers having "stand-up" elasticized flaps (barrier cuffs) which improve the containment of the leg regions. U.S. Pat. Nos. 4,695,278 and 4,795,454 issued to Lawson on September 22, 1987 and to Dragoo on January 3, 1989, respectively, describe disposable diapers having dual cuffs, including gasketing cuffs and barrier cuffs. In some embodiments, it may be desirable to treat all or a portion of the leg cuffs with a lotion, as described above.

Embodiments of the present invention may also include pockets for receiving and containing waste, spacers which provide voids for waste, barriers for limiting the movement of waste in the article, compartments or voids which accept and contain waste materials deposited in the diaper, and the like, or any combinations thereof. Examples of pockets and spacers for use in absorbent products are described in U.S. Patent 5,514,121 issued to Roe et al. on May 7, 1996, entitled "Diaper Having Expulsive Spacer"; U.S. Patent 5,171,236 issued to Dreier et al on December 15, 1992, entitled "Disposable Absorbent Article Having Core Spacers"; U.S. Patent 5,397,318 issued to Dreier on March 14, 1995, entitled "Absorbent Article Having A Pocket Cuff"; U.S. Patent 5,540,671 issued to Dreier on July 30, 1996, entitled "Absorbent Article Having A Pocket Cuff With An Apex"; and PCT Application WO 93/25172 published December 3, 1993, entitled "Spacers For Use In Hygienic Absorbent Articles And Disposable Absorbent Articles Having Such Spacer"; and U.S. Patent 5,306,266, entitled "Flexible Spacers For Use In Disposable Absorbent Articles", issued to Freeland on April 26, 1994. Examples of compartments or voids are disclosed in U.S. Patent 4,968,312, entitled "Disposable Fecal Compartmenting Diaper", issued to Khan on November 6, 1990; U.S. Patent 4,990,147, entitled "Absorbent Article With Elastic Liner For Waste Material Isolation", issued to Freeland on February 5, 1991; U.S. Patent 5,62,840, entitled "Disposable Diapers", issued to Holt et al on November 5, 1991; and U.S. Patent 5,269,755 entitled "Trisection Topsheets For Disposable Absorbent Articles And Disposable Absorbent Articles Having Such Trisection Topsheets", issued to Freeland et al on December 14, 1993. Examples of suitable transverse barriers are described in U.S. Pat. No.

5,554,142 entitled "Absorbent Article Having Multiple Effective Height Transverse Partition" issued September 10, 1996 in the name of Dreier et al.; PCT Patent WO 94/14395 entitled "Absorbent Article Having An Upstanding Transverse Partition" published July 7, 1994 in the name of Freeland, et al.; and U.S. 5,653,703 entitled "Absorbent Article Having Angular Upstanding Transverse Partition", issued Aug. 5, 1997 to Roe, et al. All of the above-cited references are hereby incorporated by reference herein.

Embodiments of the present invention may also include a waste management device 110 such as is shown in Figure 21. The waste management device 110 may include a waste bag 111 to collect feces, urine or both. The waste bag 111 may have an aperture 121 and a flange 112 surrounding the aperture for preferably adhesive attachment to the perianal area of a wearer. Further, the waste management device 110 has been found to be particularly useful and beneficial when used in conjunction with a garment, or diaper, preferably a disposable diaper. One example of a diaper 120 including a waste bag 111 is shown in Figure 22. If associated with a diaper 120 or other garment, the waste bag 111 may be disposed on or joined to any surface of the article. In one embodiment, the waste bag 111 is joined to the topsheet 124 of the diaper 120.

The waste bag 111 is preferably a flexible receptacle for the containment of excreted fecal matter or urine. Thus, the waste bag 111 is preferably liquid impermeable, and yet it may be breathable. Further, the waste bag 111 is designed of sufficient strength to withstand typical wearing conditions, such as sitting.

The waste bag 111 may comprise one or multiple layers. In one embodiment, the waste bag 111 may comprise three layers, preferably one film and two non-woven layers. Suitable film materials for any of the film layers preferably comprise a thermoplastic material. The thermoplastic material can be selected from among all types of hot-melt adhesives, polyolefins especially polyethylene, polypropylene, amorphous polyolefins, and the like; material containing meltable components comprising fibres or polymeric binders including natural fibres such as cellulose - wood pulp, cotton, jute, hemp; synthetic fibres such as fibreglass, rayon, polyester, polyolefin, acrylic, polyamid, aramid, polytetrafluoroethylene metal,

polyimide; binders such as bicomponent high melt/low melt polymer, copolymer polyester, polyvinyl chloride, polyvinyl acetate/chloride copolymer, copolymer polyamide, materials comprising blends wherein some of the constituent materials are not meltable; air and vapour permeable materials including microporous films
5 such as those described above with respect to the backsheet and monolithic breathable materials such as HYTREL available from DuPont and PEBAX available from ELF Atochem, France.

The waste bag 111 may have any shape or size. Preferred shapes include flat circular type bags, cone shaped bags, truncated cone shaped bags and pyramidal or
10 truncated pyramidal shaped bags and flat T shaped bags. Further, the waste bag 111 may be provided from a unitary piece of material or a number of separate pieces of material which may be identical or different and which may be sealed at their respective peripheries.

The waste bag 111 may also contain absorbent material. The absorbent
15 material may comprise any absorbent material which is capable of absorbing and retaining liquids. The absorbent material may comprise a wide variety of liquid-absorbent materials commonly used in disposable diapers and other absorbent articles. Some examples are described herein with respect to the absorbent core.

The waste bag 111 is provided with an aperture 121 whereby fecal matter or
20 urine is received from the body prior to storage within the bag cavity. The aperture 121 is preferably surrounded by a flange 112 and may be provided in any shape or size, such as circular, oblong, heart shaped and may be symmetrical or asymmetrical, preferably the aperture has an oblong configuration either in the longitudinal or in the transversal direction. The flange may comprise projections designed to fit the
25 perineal, genital and/or coccygeal area of the wearer.

The flange 112 should be made of soft, flexible and malleable material to allow easy placement of the flange 112 to the perianal or uro-genital area. Typical materials include nonwoven materials, wovens, open celled thermoplastic foams, closed-cell thermoplastic foams, composites of open celled foams and stretch
30 nonwoven, and films.

The waste bag 111 preferably further comprises means for joining the device to the wearer. Such means may comprise any of the joining/attachment mechanisms described herein or known in the art, and may include for example straps, belts, ties, tapes, hooks (or hook and loop) structures, and/or a body-compatible pressure sensitive adhesive applied to the wearer facing portion of the waste bag 111 or the flange. Any skin-friendly water resistant pressure sensitive adhesive may be used to join the device to the perianal or uro-genital area of the wearer, such as hydrocolloid adhesives and hydrogel adhesives. Particularly effective adhesives in providing the desired adhesive properties to secure the flange to the skin of the wearer at the sensitive perianal area, while allowing for relatively painless application and removal, are formed from crosslinking polymers with a plasticizer to form a 3-dimensional matrix.

The article of the present invention may also include one or more feces modifying agents ("FMAs", "viscous bodily waste modifying agents", "modifying agents" or "agents") in an effective concentration capable of modifying the chemical or physical properties (e.g., adhesiveness) of viscous bodily waste, such as feces and menses. As used herein, "feces modifying agent" (or FMA) refers to any chemical composition capable of increasing the hardness of a given fecal analog, or preferably actual feces, by at least about 100% or decreasing the hardness of a given fecal analog, or preferably actual feces, by at least about 25%, as measured by the Hardness Method, described below. However, depending on the particular article design and the type of feces, embodiments are contemplated which increase or decrease the effective viscosity of feces, increase or decrease the ease of dewatering the feces, decrease the stickiness of the feces, decrease the adhesion characteristics of the feces, or any combination of the above. Although the feces modifying agents of the present inventions may be capable of modifying the properties of solid feces, the FMAs are generally most effective in altering the properties of viscous fluid feces which generally have a viscosity of greater than about 10 cP and less than about 10^7 cP at a shear rate of one 1/sec, (at about 35 degrees C), and more particularly between about 10^2 cP and 10^7 cP at a one 1/sec shear rate, in a controlled stress rheometry test using parallel plates on a controlled stress rheometer. (For reference,

water is at 1.0 cP at 20 degrees C and Jif Creamy peanut butter (available from the Procter & Gamble Co., Cinti., OH) is approximately 4×10^5 cP at 25 degrees C at this same shear rate). The method for determining viscosity, as used herein, is described in detail in the Test Methods section below.

Regardless of the specific effect of the chemical agent on feces, the agent must be available to the feces in order to perform its function. As used herein, in the context of FMAs, or other compositions for enhancing feces removability, the term "available" indicates that the composition/agent is positioned within the article or presented by the article or a component of the article during the course of normal wearing of the article so as to directly contact at least a portion of the feces deposited in the article or on the wearer's skin, or so as to contact at least a portion of the wearer's skin so that the agent or composition can be transferred to at least a portion of the feces. If the composition/agent is positioned within a structure (e.g., in an absorbent layer under a topsheet) the structure must be substantially penetrable by the feces. In such cases, the agent is "available" if the structure has an Acceptance Under Pressure greater than about 0.50 g/cm²/I, and preferably greater than about 1.0 g/cm²/I, as measured by the Acceptance measurement described in the Methods section below. If the agent is encapsulated, it should be released by the article at or about the time when the feces insults the article. For example, the FMA may be retained by a water-soluble film which, upon contact with urine or fecal water, dissolves and releases the FMA to contact the feces and/or skin.

An "effective concentration" of an FMA, as used herein, refers to the relative amount of the agent required to have a measurable effect on the Hardness (as measured by the Hardness Method described below) of at least a portion of the feces in the article or on the skin of the wearer. Data illustrating an "effective concentration" is provided below. Preferably, a concentration of an FMA of at least about 0.01 weight percent of the feces to be treated is desirable, and more typically between about 0.1 and about 50 weight percent of the FMA is available to the feces. For example, to treat an entire 25 gram feces loading in a diaper (i.e., a "bulk" treatment) at a 5 weight percent level, 1.25 grams of the FMA must be available to the fecal mass (assuming the specific gravity of the feces is 1.0). Thus, the FMA is

preferably present in the article in concentrations ranging from about 0.001% to about 50% by weight of the article. Typically, however, the concentration is between about 0.01 and about 20 weight percent of the article.

The FMA is preferably capable of reducing the Hardness of a fecal analog, and preferably, actual feces, by about 25% or increasing the Hardness by about 100% at a concentration of no more than about 20 weight percent of the feces to be treated at room temperature (20-25°C). More preferably, the FMA is capable of reducing the Hardness of a fecal analog or actual feces by about 25%, or increasing the Hardness by about 100% at a concentration of no more than about 10 weight percent of the feces to be treated. Even more preferably, the FMA is capable of reducing the Hardness of a fecal analog or actual feces by about 25%, or increasing the Hardness by about 100% at a concentration of no more than about 5 weight percent of the feces to be treated. In other preferred embodiments, the FMA is capable of reducing the Hardness of a fecal analog or actual feces by 25%, or increasing the Hardness by about 100% at a concentration of no more than about 1 weight percent of the feces to be treated. In yet other preferred embodiments, the FMA is capable of reducing the Hardness of a fecal analog or actual feces by about 25%, or increasing the Hardness by about 100% at a concentration of no more than about 0.5 weight percent of the feces to be treated. Typically, the FMA is capable of reducing the Hardness of a fecal analog or actual feces by about 25%, or increasing the Hardness by about 100% at a concentration of between about 0.1 and about 10 weight percent of the feces to be treated.

Preferably, the defined reduction or increase in Hardness is effected within the range of within about 30 minutes, more preferably within about 15 minutes, even more preferably within about 5 minutes, even more preferably within about 3 minutes, and most preferably in about 1 minute after contact with the feces. Typically, the desired Hardness change is effected within the range of about 1 minute to about 10 minutes. In more preferred embodiments, the defined reduction or increase in Hardness is effected within about 3 minutes at an FMA concentration of no more than about 5% by weight of the feces to be treated or within 3 minutes at an FMA concentration of about 1.5% by weight of the feces to be treated. In other

preferred embodiments, the FMA is capable of increasing the Hardness of a fecal analog, or actual feces, by about 200% within about 3 minutes at a concentration of no more than about 5%. In yet other preferred embodiments, the FMA is capable of increasing the Hardness of a fecal analog, or actual feces, by about 400% within about 3 minutes at a concentration of no more than about 5%.

In other preferred embodiments, the FMA is capable of reducing the Hardness of a fecal analog, or actual feces, by about 50% within about 3 minutes at a concentration of no more than about 5%.

The reference Hardness values of two synthetic fecal analog materials are presented in Table I. (Hardness has been found to be closely related to the complex modulus of feces.) Analog A represents the water content, Hardness, and adhesion properties of typical "runny" feces, while Analog B represents typical "pasty" feces. Two consistencies of feces are simulated so as to better illustrate the activity of the FMAs. The methods of preparing Analogs A and B are described in the Test Methods section below.

TABLE I

<u>Fecal Analog</u>	<u>Fecal Analog Hardness (g)</u>
A	8.6
B	620

Fecal analogs A and B provide a robust and repeatable means to evaluate FMA performance. However, actual feces is a very complex material. For certain chemical treatments, the FMA effect may be greater for actual feces than for either of the analogs described above. For one of the agents evaluated, Hardness data is presented in terms of hardness change for feces analogs and actual feces, in order to demonstrate the similarity in relative responses to the treatment. The actual feces used in these experiments consisted of both a composite "runny" feces sample and a composite "pasty" feces sample. The composite runny feces sample was pooled using several bowel movements (uncontaminated by urine) produced by two U.S. breast-fed, four month old, male infants. The composite "pasty" sample was pooled using several bowel movements (uncontaminated by urine) produced by two U.S. infants –

a four month old, formula-fed male and a 12 month old male eating a “transition” diet between breast milk and table food. Feces pooling was accomplished via a Seward Stomacher 400 Lab System by Seward Medical, Ltd. of London, UK. For reference, the Hardness of the untreated (i.e., as collected) pooled runny feces sample was 28 grams, and the Hardness of the untreated pooled pasty feces sample was 297 grams.

The effect of mixing several comparative examples with fecal analogs are illustrated in Table II below. All comparative materials were mixed with the fecal analog as described below in the Sample Preparation Method. As is evident in the data above, the desired changes in Hardness were not achieved by the comparative materials.

TABLE II

<u>Fecal Analog</u>	<u>Comparative Additive</u>	<u>Concentration (wt.%)</u>	<u>Treated Fecal Analog Hardness (g)</u>
A	Corn Starch	1.0	12.6
	(Dietary Fiber Control, Sigma Chemical Co., St. Louis, MO, S-2388)	5.0	8.6
	Pure Corn Starch Baby Powder (Johnson & Johnson, Co., Skillman, NJ)	1.0	14.4
A	Baby Powder (talco) (Johnson & Johnson, Co.)	5.0	7.1
		1.15	10.2
B	Corn Starch	1.1	643
	(Dietary Fiber Control, Sigma Chemical Co., St. Louis, MO, S-2388)	4.9	533
	Baby Powder (talco) (Johnson & Johnson, Co.)	1.0	854
B		5.0	679

The Feces Modifying Agent of the present invention may include one or more “water liberating” agents capable of separating the liquid portion of the feces (i.e., water) from the solid structure of the feces and/or reducing the degree of “binding” of the feces water to the solid feces components. Without wishing to be bound by theory, it is believed that feces comprises water in several states. For example, the

feces includes free water, bound water (bound water may be held in a “colloidal” structure via an electrical double layer on the surface of the particles, organized in a polymeric “gel” structure, or associated with other charged elements in the fecal matrix), and entrapped water (e.g., inside bacteria). It is also believed that the solid and polymeric components of the feces act to organize bound water into higher energy states (i.e., more energy is required to separate the water from the matrix) as compared to free water or “unbound” water. (The solid components of feces (soluble and insoluble) generally include one or more of the following; undigested food material (e.g., fiber), bacteria, long chain polysaccharides, fats, soaps, protein globules, and the like.) The water content of viscous bodily wastes such as fecal material is relatively high, generally greater than 50%, and often between about 60% and about 95% by weight. However, conventional absorbent articles are incapable of separating much of the water from the fecal matrix. (As used herein, the term “fecal matrix” refers to the feces as a whole, including any solid or soluble components such as bio polymers.) Thus, very little of the feces (generally only a portion of the free water) is actually absorbed such that it can be adequately contained.

Including “water liberating” agents, which act to separate the bound and/or entrapped water from the fecal matrix, in the FMAs or other compositions of the present invention may improve the efficacy of the absorbent structure with regard to feces, and/or the removability of feces from the wearer’s skin. “Liberated water” in feces or analogs may remain within the feces mass resulting in reduced feces viscosity, or completely separate from feces forming two distinct phases, water and the remaining feces. If the water is completely separated, the remaining feces becomes significantly harder and less adhesive. In the absence of absorbent materials in contact with the feces, liberation of water from the fecal matrix decreases the viscosity of the overall fecal mass by permitting the liquid portion of the fecal matter to flow more freely. If, however, the liberated water is completely separated from the fecal mass, the viscosity or hardness of the remaining feces will be increased. Further, the removal of water helps to agglomerate the fecal solids into more discrete solid particles which are generally more strongly associated with each other than when held in the matrix (it is believed that a reduction in inter-particle repulsive

forces causes the particles to aggregate and release water held between them). The feces' decrease in viscosity generally reduces its adhesion to the skin and promotes its penetration into the absorbent structure. Accordingly, the absorbent article's overall performance may be significantly improved.

5 While the liberation of water caused by the destabilization of the colloidal or gel nature of the feces preferably decreases the viscosity and adhesion of the feces and increases the ability of the feces to flow into the absorbent structure, it may also enhance the ability of any absorbent materials in contact with the treated feces to dewater and immobilize the feces. However, in some embodiments it may be
10 undesirable to have immobilization occur on the surface of the absorbent structure because the solid fraction of the feces may still be accessible to the user. Thus, it may be preferred to limit the contact of viscous bodily waste with absorbent media until the feces has penetrated the structure to the desired depth or location for immobilization away from the user. In such embodiments, the feces viscosity is
15 preferably decreased while on the surface of, or prior to contact with the absorbent structure, and dewatered and/or immobilized once it has sufficiently penetrated the structure.

Feces Modifying Agents which act to decrease the viscosity of feces as described above include, but are not limited to the following: organic and inorganic
20 flocculants, and the like. Inorganic flocculants include but are not limited to divalent and trivalent metal salts, including but not limited to salts of iron, aluminum, calcium, and sodium and mixtures thereof. It is believed that such salts form hydrolysis products which associate with the charged surfaces of the particulate matter in the feces colloidal structure, resulting in flocculation (i.e., flocculation via any of the
25 mechanisms described above). Some examples include ferrous chloride, ferric chloride, aluminum sulfate, aluminum chloride hydroxide, sodium aluminate, calcium sulfate, poly-aluminum-silicate-sulfate (available from Handy Chemical, Quebec under the trade name PASS), ferrous sulfate, calcium carbonate, and the like.

Organic flocculants include but are not limited to natural substances like
30 albumin, xanthan gum, and guar gum. Synthetic flocculants are generally non-crosslinked, water-soluble molecules or polymers and may include acrylic and

acrylamide polymers and their derivatives (in very low concentrations (a few hundredths of a weight percent)), polyvinyl pyrrolidone, poly methacrylates, polyamines, polyethylene oxide, and allylamine polymers. Preferably, these are cationic polymeric species. (Although applicants do not wish to be bound by theory, it is believed that these agents function by associating with the negatively charged regions of the feces particulate fraction and reducing the net inter-particle repulsive charge.) Some of the synthetic flocculants may act to increase the viscosity of aqueous solutions if used in high concentrations and will be discussed below as feces thickening agents. It is also important to note that if some of the organic flocculants are used in too high a concentration their effect may be reversed. Thus, the water may be held more tightly by the feces due to the tendency of these agents to form gels if used in excess of the amount necessary to associate with the charged particulates.

Without wishing to be bound by theory, it is believed that flocculants destabilize colloids by enhancing aggregation of the constituent particles in the matrix via any of a number of mechanisms, including charge neutralization, bridging, and electrostatic patching. Flocculation of colloidal systems via charge neutralization occurs when the agent adsorbs to the surface of the constituent particles and reduces the electrical double-layer potential. The agent acts in theory, to reduce the stabilizing repulsive surface charges at the surface of the solid particles in the matrix by accumulating at the charged interfaces of the particles, allowing the particles to aggregate. Thus, the water that was held "bound" in the matrix (i.e., held between the particles) is freed as the structure collapses. It is believed that "bridging" may occur when a long-chain polyelectrolyte adsorbs onto particles in the colloidal matrix and extends into the bulk of the matrix, where it can span the distance of closest approach of other particles in the matrix. This results in the aggregation of particles and the freeing of bound water. "Electrostatic patching" may occur where, as the flocculating polymer is completely adsorbed onto the particle, geometric limitations prevent complete charge neutralization. This may result in the formation of positive "patches" or areas on the particles that attach to negative patches on other particles

upon collision. This also results in aggregation of the particles due to the net reduction in electrical repulsion between the particles.

Some crosslinked derivatives of the synthetic organic flocculants (e.g., polyacrylates), or derivatives thereof, are known in the art as superabsorbent polymers, and function to form water-insoluble gels upon contact with very low viscosity aqueous wastes such as urine and menses. However, because these crosslinked species cannot readily dissociate (i.e., dissolve) and adsorb to the particulate species within the feces matrix, they do not function as flocculants.

Viscosity reduction performance of several representative water-liberating agents is illustrated in the data in Table III. The mixing of the agent and the fecal analog or feces is described below in the Sample Preparation Method).

TABLE III

<u>Fecal Analog</u>	<u>Flocculant</u>	<u>Concentration (wt. %)</u>	<u>Treated Fecal Analog Hardness (g)</u>	<u>% Change in Hardness</u>
A	calcium hydroxide (ACS Reagent, Sigma Chemical Co., St. Louis, MO C-5551)	1.1	5.7	(34) *
A	calcium sulfate hemihydrate (#30, 766-1 Aldrich Chemical Co., Milwaukee, WI)	1.0	4.9	(43)
B	polyvinyl pyrrolidone (PVP) (Avg. MW = 40,000, k-value: 29-32, Sigma PVP-40)	1.0	425	(31)
B	sodium polymethacrylate (30 wt% solution in water, Avg. MW = 6000, Avg. Mn = 4000, Aldrich #43, 449-3)	2.4	446	(28)
B	sodium polymethacrylate	4.7	411	(34)

* () indicates decrease in the value.

Feces Modifying Agents which act to decrease the viscosity and/or adhesion of feces as described above may also include reducing agents. For example, agents that reduce disulfide bonds (-S-S-bonds) as found in colonic mucous colomin mucous generally comprises (macromolecular glycoproteins linked by disulfide bonds) can effect a significant viscosity reduction in feces having high mucous content. While not wishing to be bound by theory, it is believed that reduction of the mucin disulfide bonds (which function as crosslinks between mucin polymer chains) significantly reduces the average molecular weight of the glycoprotein structure in feces such as runny feces to a level well below the "gel point" of the mucin (i.e., long-distance structure becomes impossible due to the relatively small size of the glycoproteins). Exemplary reducing agents include sulfites such as sodium hydrogensulphite, sodium sulfite and sodium dithionite, thiols and thiol alcohols (e.g., 2-mercaptoethanol, dithiothreitol, and dithioerythritol), mercaptoacetic acid, sodium thioglycolate, thiolactic acid, thioglycolamide, glycerol monothioglycolate, borohydrides (e.g., sodium borohydride), tertiary amines, thiocyanates such as sodium thiocyanate, thiosulfates such as sodium thiosulfate, thiophosphates such as sodium thiophosphate, arsenites such as sodium arsenite, phosphines such as triphenyl phosphine, phenols such as thiophenol and p-nitrophenol, betaines, and others including, but not limited to, lithium aluminumhydride, aluminum chloride, guanidine hydrochloride, stannous chloride, hydroxylamine, and $\text{LiHB}(\text{C}_2\text{H}_5)_3$.

Viscosity reduction performance of a representative reducing agent (mixed with a fecal analog and actual feces as described in the Sample Preparation Method in the Test Methods section below) is illustrated in the data in Table IV.

Feces /Fecal Analog	Reducing Agent	TABLE IV		
		Concentration (wt. %)	Treated Feces/Fecal Analog Hardness (g)	% Change in Hardness
Composite Runny Feces Sample	sodium hydrogensulfite (Aldrich.# 24,397-3)	5.0	10.1	(50) *
B	sodium hydrogensulfite (see above)	5.0	311	(64)

* () indicates decrease in the value.

In other particularly preferred embodiments of the present invention, modifying agents which generally increase the structure of the feces by increasing the degree of water binding are employed to increase the viscosity and reduce the adhesion and mobility of the feces. This may be accomplished via the use of thickening agents in the appropriate concentrations. Thickening agents may be natural or synthetic and are generally water-soluble, (typically non-crosslinked) polymers, such as CMC (carboxymethyl cellulose), hydroxypropyl methylcellulose, hydroxyethyl cellulose, polyacrylic acid and its derivatives, carageenan, polyacrylamide and its derivatives, (polyethylene)imines, gums (such as xanthan, guar, karaya, agar, locust bean gum, pectin, and gum ghatti, or mixtures thereof) and other similar materials. Cationic polymers are preferred due to the anionic surfaces of fecal bacteria and biopolymers. Thickening agents increase the viscosity of the feces by dissolving in the free water in the feces and osmotically “binding” water, thereby increasing the solid “structure” of the feces. Generally, large, insoluble polyelectrolytic polymeric particles such as conventional superabsorbents are not able to dissolve in the feces free water and create a matrix within the feces at the molecular level. Some FMAs may perform differently on different types of feces (e.g., a FMA that acts as a flocculant on one type of feces, may act as a thickening agent on another type due to variance in the structural character of the specific type of feces). One example of this is calcium hydroxide which functions as a flocculant for a runny fecal analog, but as a thickener for a pasty fecal analog in the same concentrations.

Table V shows the effects of concentration of various FMAs acting as thickening agents on the fecal analogs and/or feces. The mixing of the agent and the fecal analog or feces is described below in the Sample Preparation Method.

TABLE V

<u>Feces/Fecal Analog</u>	<u>Thickener</u>	<u>Concentration (wt. %)</u>	<u>Treated Feces/Fecal Analog Hardness (g)</u>
A	Gum Guar	1.1	35
	(Sigma G-4129)	5.0	110
A	poly(acrylamide	1.2	9.6
	co-acrylic acid)	4.9	101
	(Avg. mw = ca. 5×10^6 , Aldrich # 18,127-7)		
A	poly acrylamide	1.0	130
	(ground into powder, Sigma P-2433)	5.0	536
B	carboxymethyl cellulose (CMC)	2.5	55
		5.0	368
		10.0	935
B	Gum Xanthan	2.5	56
	(practical grade, Sigma G-1253)	10.0	362
B	carageenan	5.0	1641
	(Type I, commercial grade, Sigma C-1013)		
composite runny feces sample	carageenan (see above)	5.0	150
B	hydroxypropyl methylcellulose (Sigma H-7509)	5.0	1775
composite runny feces sample	hydroxypropyl methylcellulose (see above)	5.0	111
composite pasty feces sample	hydroxypropyl methylcellulose (see above)	5.0	1060

In still other preferred embodiments, the modifying agent comprises an ionic complexing agent. Ionic complexing agents may include any single component which complexes with itself or water or other chemical entities in the feces to form regions of increased structure and rigidity within the feces. The resultant complex acts to stabilize or bind water more tightly in the feces. Exemplary ionic complexing agents include ZnO, MgO, MnO, CaO, calcium hydroxide, Al₂O₃, aluminum salts, zinc salts such as zinc acetate and zinc gluconate, gelatin, quaternary ammonium salts, ethanolamines, alginic acid, cetyl trimethyl ammonium bromide and the like. Alternatively, the ionic complexing agent may comprise a two (or more) component system, wherein the complex (i.e., longer-range structure) is created by the interaction of the two added components (e.g., aluminum, calcium, or zinc salts plus alginic acid and/or salts thereof). The ionic complexing agents may form crystal hydrates when complexing with water. In general, calcium-containing compounds or systems (e.g., CaO, calcium hydroxide, and calcium alginate, etc.) are some of the most effective feces modifying agents.

Table VI shows the effect of various ionic complexing agents on fecal analog or feces Hardness. (Mixing of the fecal analog and/or feces was performed as specified in the Sample Preparation Method below.)

TABLE VI

<u>Fecal</u> <u>Analog/Feces</u>	<u>Ionic Complexing Agent/System</u>	<u>Concentration</u> <u>(wt. %)</u>	<u>Treated Fecal</u> <u>Analog/Feces</u> <u>Hardness (g)</u>
A	calcium oxide	1.0	26
	(Sigma C-2178)	5.0	385
A	alginate acid/zinc chloride	5.0	114
	(50%/50% by wt.)	(total mixture)	
	(alginate acid - sodium salt, from kelp, "high viscosity"-Sigma A-7128; zinc chloride- Sigma Z-4875)		
B	calcium hydroxide	1.0	1206
	(ACS reagent, Sigma C-5551)	5.0	1223
B	zinc oxide	5.1	1192
	(ACS reagent, Sigma Z-1753)		
B	sodium chloride	5.2	1275
	(ACS Reagent, Sigma S-9888)		
B	calcium chloride	4.9	1405
	(anhydrous, Sigma C-4901)		
A	alginate acid, ammonium-calcium salt (Sigma A-7253)	5.0	513
B	alginate acid, ammonium-calcium salt (Sigma A-7253)	5.0	2070
Composite runny feces	alginate acid, ammonium-calcium salt (Sigma A-7253)	5.0	52
Composite pasty feces	alginate acid, ammonium-calcium salt (Sigma A-7253)	5.0	908

In still other preferred embodiments, the FMA includes a crosslinker that can
 5 react with functional groups on the components of the feces or with itself to form
 long distance structure in the fecal matrix. The crosslinking effect uses the fecal
 components as "monomers" that are linked together by a multifunctional (e.g.,

difunctional) modifying agent to form a longer-range network structure. Such modifying agents may target amine groups (e.g., dialdehydes, dialdehyde starches), hydroxyl groups (e.g., epichlorohydrin), and/or carboxyl groups (e.g., diamines). Other exemplary FMA crosslinking agents are Kymene 557-H, 557-LX, and 2064 (available from Hercules, Inc. of Wilmington, DE). Table VII shows the effects of an exemplary crosslinking agents on fecal analog Hardness after 15 minutes ($t = 15$ minutes after beginning the stirring process, as described in the Sample Preparation Method below).

TABLE VII

Analog	Crosslinking Agent	Concentration (%)	Fecal Analog Hardness
B	Kymene 2064 (Hercules, Inc., Wilmington, DE)	5.0	1405

While in certain embodiments it is desirable to treat the entire mass of feces within the article (i.e., "bulk" treatment), in some preferred embodiments only a portion of the feces is treated with the FMA. In these embodiments the FMA may penetrate only a relatively small distance into the feces, thereby forming a modified external layer that is relatively stiff and non-sticky (i.e., significantly less adhesive). This may be preferable from an FMA utilization standpoint or to eliminate the need for mixing of the FMA into the fecal mass. The modified external layer is a region or layer of feces at or near the surface of the feces mass with different physical properties than the remainder of the feces mass. Preferably, the modified layer is harder (i.e., has a higher yield stress), less sticky, and/or has a higher resistance to diffusion of volatile molecules contained in the feces than does the remaining feces, resulting in decreased spreading/mobility of the feces mass and/or decreased adhesion of the feces mass to the wearer's skin and/or reduced fecal odor. Preferably, the modified external layer region is between about 1 and about 1000 microns in thickness and may cover all or any portion of the fecal mass. For example, it may be suitable to treat only the feces at the skin/feces interface (e.g., to reduce adhesion

and/or promote cleaning or reduce spreading across the wearer's skin or to promote absorption or to reduce spreading within the article). Thus, to treat a 1 millimeter thick layer of a fecal mass over a 30 square cm area of the skin or article topsheet at a 10 weight percent level, 0.30 grams of the FMA must be available to the feces in the region of contact with the feces (assuming the specific gravity of the feces is 1.0).

In various embodiments, the FMA may be organic or inorganic, a low molecular weight molecule or polymeric in nature, and/or may be a liquid, solid (e.g., powder, fiber, film, web), or a semi-solid, or combinations thereof. The FMA may include, or be combined with, any anti-adherent as known in the art, such as TEFLON microparticles. The FMA may be presented in a water/oil or oil/water emulsion, a suspension, or mixture. The FMA may be disposed in the article as an individual discrete element (e.g., as a fibrous batt or layer within or attached to the article) or may be associated with (e.g., at least temporarily held in or on) a carrier vehicle, such as a lotion or skin care composition (described below), a web, a film, a fibrous structure such as a brush, a loop structure such as used for a loop fastening component as described above, or in a packet, cell or envelope which releasably encapsulates the FMA.

In embodiments wherein the FMA is delivered to the feces and/or skin via a skin care composition, it may be soluble in the skin care composition or may be held in suspension or as a simple mixture. Larger FMA particles (e.g., preferably greater than about 250 microns in largest dimension) may be at least partially embedded in or held adhesively by the skin care composition. Some exemplary materials useful in the skin care compositions which may be used in embodiments of the present invention include Category I actives as defined by the U.S. Federal Food and Drug Administration's (FDA) Tentative Final Monograph on Skin Protectant Drug Products for Over-the-Counter Human Use, which presently include: allantoin, aluminum hydroxide gel, calamine, cocoa butter, dimethicone, cod liver oil (in combination), glycerine, kaolin, petrolatum, lanolin, mineral oil, shark liver oil, white petrolatum, talc, topical starch, zinc acetate, zinc carbonate, zinc oxide, and the like. Other potentially useful materials are Category III actives as defined by the U.S. Federal Food and Drug Administration's Tentative Final Monograph on Skin

Protectant Drug Products for Over-the-Counter Human Use tentative final monograph on skin protectant drug products for over-the-counter human use, which presently include: live yeast cell derivatives, aldioxa, aluminum acetate, microporous cellulose, cholecalciferol, colloidal oatmeal, cysteine hydrochloride, dextranpanthol, 5 Peruvian balsam oil, protein hydrolysates, racemethionine, sodium bicarbonate, Vitamin A, and the like. Many of the FDA monographed skin care ingredients are currently utilized in commercially available skin care products, such as A and D® Ointment, VASELINE® Petroleum Jelly, DESITIN® Diaper Rash Ointment and Daily Care Ointment, GOLD BOND® Medicated Baby Powder, AQUAPHOR® 10 Healing Ointment, BABY MAGIC® Baby Lotion, JOHNSON'S ULTRA SENSITIVE® Baby Cream, Johnson's baby lotion, lip balms, etc. Other suitable skin care compositions are described in detail in U.S. Patent No. 5,643,588, U.S. Patent No. 5,607,760, U.S. Patent No. 5,609,587, and U.S. Patent No. 5,635,191. The disclosures of each of these patents is incorporated herein by reference.

15 The skin care compositions useful in the present invention preferably have a melting profile such that they are relatively immobile and localized on the wearer-contacting surface of the article at room temperature, are readily transferable to the wearer at body temperature, and yet are not completely liquid under extreme storage conditions. Preferably, the compositions are easily transferable to the skin by way of 20 normal contact, wearer motion, and/or body heat.

In preferred embodiments, the skin care compositions useful herein are solid, or more often semi-solid, at 20°C, i.e. at ambient temperatures. By "semisolid" is meant that the composition has a rheology typical of pseudoplastic or plastic liquids. When no shear is applied, the compositions can have the appearance of a semi-solid 25 but can be made to flow as the shear rate is increased. This is due to the fact that, while the compositions may contain primarily solid components, they may also include some minor liquid components. Preferably, the compositions of the present invention have a zero shear viscosity between about 1.0×10^6 centipoise and about 1.0×10^8 centipoise. More preferably, the zero shear viscosity is between about 30 1.0×10^6 centipoise and about 5.0×10^7 centipoise. As used herein the term "zero shear viscosity" refers to a viscosity measured at very low shear rates (e.g., 1/sec)

using plate and cone viscometer (a suitable instrument is available from TA Instruments of New Castle, DE as model number CSL 100). One of skill in the art would recognize that using means other than high melting point components can be used to provide comparable viscosities. For example, the lotion could be provided with a structure which has a high zero shear viscosity but, on the application of shear, such structure collapses with a resulting viscosity reduction (Compositions of this type are said to have a yield value.) Such structure can be provided by certain clay materials, such as bentonite clays or montmorillonite clays, and by fumed silica. Particularly preferred are the fumed silicas as are available from the Cabot Corp., Cab-O-Sil Div. Of Tuscola, IL as CAB-O-SIL. A skilled person would also recognize that the zero shear viscosity of such compositions may be measured by extrapolating a plot of viscosity vs. shear rate to a shear rate of zero. Such viscosity measurements should be conducted at a temperature of about 20°C.

The skin care composition carrier vehicle may include a useful active ingredient such as one or more skin protectants or emollients. As used herein, the term "emollient" refers to a material that protects against wetness or irritation, softens, soothes, supple, coats, lubricates, moisturizes, protects and/or cleanses the skin. (It will be recognized that several of the monographed actives listed above are "emollients", as that term is used herein.) In a preferred embodiment, emollients will have either a plastic or liquid consistency at ambient temperatures, i.e., about 20°C. Such a consistency allows the composition to impart a soft, lubricious, lotion-like feel.

Representative emollients useful in the present invention include, but are not limited to, emollients that are petroleum-based, such as petroleum oils and/or waxes; sucrose ester fatty acids; polyethylene glycol and derivatives thereof; humectants; fatty acid ester type; alkyl ethoxylate type; fatty acid ester ethoxylates; fatty alcohol type; polysiloxane type, such as silicone oils and/or waxes; propylene glycol and derivatives thereof; glycerine and derivatives thereof, including glyceride, acetoglycerides, and ethoxylated glycerides of C₁₂-C₂₈ fatty acids; triethylene glycol and derivatives thereof; spermaceti or other waxes; fatty acids; fatty alcohol ethers, particularly those having from 12 to 28 carbon atoms in their fatty chain, such as

stearic acid; propoxylated fatty alcohols; other fatty esters of polyhydroxy alcohols; lanolin and its derivatives; kaolin and its derivatives; any of the monographed skin care agents listed above; or mixtures of these emollients.

Another preferred component of the skin care composition carrier vehicles
5 useful in the present invention is an agent capable of immobilizing the composition (including the preferred emollient and/or other skin conditioning, therapeutic or protective agents and/or the FMA(s) present in the composition) in the desired location in or on the treated article. The immobilizing agent may counteract the tendency of an emollient to migrate or flow by keeping the emollient primarily
10 localized on the surface or in the region of the article to which the composition is applied. This is believed to be due, in part, to the fact that the immobilizing agent raises the melting point and/or viscosity of the composition above that of the emollient. Since the immobilizing agent is preferably miscible with the emollient (or solubilized in the emollient with the aid of an appropriate emulsifier or dispersed
15 therein), it entraps the emollient on the surface of the article's wearer contacting surface or in the region to which it is applied.

It is also advantageous to "lock" the immobilizing agent on the wearer contacting surface or the region of the article to which it is applied. This can be accomplished by using immobilizing agents which quickly set up (i.e., solidify) upon
20 application to the article. In addition, outside cooling of the treated article via blowers, fans, cold rolls, etc. can speed up crystallization of the immobilizing agent.

In addition to being miscible with (or solubilized in) the emollient, the immobilizing agent preferably has a melting profile that provides a composition that is solid or semisolid at ambient temperature. In this regard, preferred immobilizing
25 agents have a melting point of at least about 35°C. This prevents the immobilizing agent from having a tendency to migrate or flow. Preferred immobilizing agents will have melting points of at least about 40°C, and more typically in the range of from about 50° to about 150°C.

Immobilizing agents suitable for use in the present invention can be selected
30 from any of a number of agents, so long as the preferred properties of the skin care composition provide the skin benefits described herein. Preferred immobilizing

agents generally comprise a member selected from the group consisting of C₁₄-C₂₂ fatty alcohols, C₁₂-C₂₂ fatty acids, and C₁₂-C₂₂ fatty alcohol ethoxylates having an average degree of ethoxylation ranging from 2 to about 30, and mixtures thereof. Preferred immobilizing agents include C₁₆-C₁₈ fatty alcohols, preferably crystalline high melting materials selected from the group consisting of cetyl alcohol, stearyl alcohol, behenyl alcohol, and mixtures thereof. (The linear structure of these materials can speed up solidification on the treated absorbent article.) Other preferred immobilizing agents include C₁₆-C₁₈ fatty acids, preferably selected from the group consisting of palmitic acid, stearic acid, and mixtures thereof. Still other preferred immobilizing agents include C₁₆-C₁₈ fatty alcohol ethoxylates having an average degree of ethoxylation ranging from about 5 to about 20. Preferably, the fatty alcohols, fatty acids and fatty alcohols are linear. Importantly, these preferred immobilizing agents such as the C₁₆ - C₁₈ fatty alcohols increase the rate of crystallization of the composition causing the composition to crystallize rapidly onto the surface of the substrate. Yet other types of ingredients suitable for use as immobilizing agents, either alone, or in combination with the above-mentioned immobilizing agents, include waxes such as carnauba, ozokerite, beeswax, candelilla, paraffin, ceresin, esparto, ouricuri, rezowax, isoparaffin, and other known mined and mineral waxes.

The Feces Modifying Agent may be delivered to the feces directly via transfer of the FMA to the feces or it may initially transfer to the wearer's skin or other element of the article prior to transfer to the feces. The carrier vehicle may be integral with the disposable article or may constitute, or be component of, a separate article to be applied to the wearer (preferably at least over the perianal region) prior to, or in place of, a diaper, training pant, underwear, or other article.

The means for joining the FMA to a carrier vehicle may include any means known in the art, such as adhesives (particularly water soluble adhesives), hydrogen bonding, releasable encapsulation, spraying, coating, and the like. Hydrogen bonding of the FMA to a substrate may be effected by slightly wetting either the FMA or at least a portion of the substrate with water. Upon drying, the FMA is releasably affixed to the substrate (i.e., subsequent contact with liquid water will break the

bond). This effect is enhanced for those FMAs which “gel” and become sticky when wet (e.g., CMC, hydroxy propyl cellulose, alginic acid and derivatives, etc.). Wetting may be accomplished by subjecting either the FMA, substrate, or both to a high humidity environment (e.g., 80% RH or greater) prior to or at the time of contact. Alternatively, water may be sprayed, misted, or atomized over at least a portion of either the agent or substrates prior to or at the time of their contact. In such cases, the structure is preferably dried prior to incorporation into an article.

The FMA may contact the feces at or near the surface of the article (e.g., at the topsheet/feces interface), within the article (as in a waste management element 120 as described below), or at the body-side surface of the fecal mass (i.e., having first been transferred to the skin or other surface above the plane of the article). Typically, the FMA will contact the feces in the region of the article associated with the wearer’s anus (e.g., crotch region in a diaper context). The feces may alternatively contact the FMA as it passes through an orifice, flange, valve, or the like, at or near the anus of the wearer. In such cases, the FMA may be expressed or drawn from the orifice or valve (e.g., from reservoirs) by the pressure of the passage of the feces as it extrudes from the body. The orifice may comprise a slit, slot, or perforation in a sheet, envelope, packet or other structure containing the FMA or composition comprising a FMA disposed in proximity to the exit point of the feces from the body. The orifice may be initially sealed by soluble film that is dissolved by contact with the feces, releasing the agent or composition. Alternatively, the orifice may be opened as the structure is deformed by passage or pressure of the feces. The feces pressure, in addition to body pressure and movement may aid in the expression of FMA through the orifice to the feces.

In other preferred embodiments, the FMA may be associated with a gasket such as a leg cuff, waist barrier, waistband, waste pocket or with a feces spacing element. In embodiments wherein the FMA is associated with a gasketing element such as a leg cuff, waist barrier, or waist pocket, it is preferred that the FMA be associated with the portion of the gasket disposed closest to the exit point of the waste from the wearer (e.g., the anus for feces). In certain preferred embodiments, the FMA is releasably attached to the surface of the gasket material so as to promote

treatment of the feces and/or skin contacting the gasket. The FMA may be releasably attached to the gasket surface via any of the means described above or any other means known in the art. In other embodiments, the FMA is releasably encapsulated at or near at least a portion of the gasket surface. In embodiments including feces
5 spacing elements, any portion of the spacing element may comprise one or more FMAs. The spacing element may be releasably coated with the agent as described above or may comprise cells, packets, or pouches of the agent covered, at least in part, with a water or feces-soluble film (as described above).

The FMA may be delivered passively (e.g., the feces flows and contacts it
10 during normal wearing conditions or the FMA is released to the feces and/or skin as a result of normal wearer movement and/or pressure), actively (e.g., an element in the article responds to a signal and delivers/releases the FMA to the feces), or via a secondary carrier (e.g., a powder or other skin care composition initially transferred to the wearer's skin). Delivery of the FMA to the feces may occur as a result of
15 feces extrusion pressure, weight, temperature, enzyme activity, water content, and/or pH; urine presence (e.g., urine triggering release of the agent in response to or in anticipation of a defecation); body motions, pressure, or heat; or any other trigger or event during the wear cycle of the article.

The FMA may be initially stored within or on the article or any portion thereof
20 and subsequently released by any of the triggering events described herein. In certain preferred embodiments, the FMA is releasably encapsulated under a film, in cells, packets, envelopes and the like so as to prevent migration and/or loss of the agent prior to the article being insulted by feces and/or to aid in positioning the FMA for contact with the feces during use. The film covering, cells, packets, or other
25 "containers" for the agent may comprise a water-soluble film over at least the feces-contacting surface area of the container. The water from urine, feces, or other feces dissolves the film releasing the agent (i.e., triggering release) to contact and treat the feces. An example of a water soluble film useful in the present invention is a polyvinyl alcohol film available as MONOSOL M7031 from Chris Craft Industrial products of
30 South Holland, IL or HL1636 from the H. B. Fuller Co. of St. Paul, MN.

Alternatively, the film may be soluble only in the presence of certain fecal enzymes (like trypsin) or in certain pH ranges.

The release of the agent may be rapid (such as with an explosive gas release created by contacting urine or fecal water with a gas-evolving composition) to embed or coat the feces with the agent. The gas evolving composition may comprise particles, globules, etc. of one or more substances which evolve gas when mixed with or together in water (e.g., sodium bicarbonate or sodium bicarbonate and citric acid). The particles may be embedded in a water soluble matrix (e.g., PVA). The FMA may be disposed on or attached to the waste contacting surface of the film or may be embedded in the water soluble film between the gas-evolving composition and the feces contacting surface. Thus, for example, when water present in the feces dissolves the water-soluble film, the gas-evolving composition is activated (i.e., the component(s) mix with the water) and gas is evolved rapidly, forcing mixing of the FMA and the feces. The particles may comprise combinations such as citric acid and sodium bicarbonate which, when mixed with water, rapidly releases carbon dioxide gas. Alternatively, the gas-evolving composition may comprise water soluble capsules containing compressed gas and the FMA. Water from the feces which contacts the capsules can act to dissolve the film and release the gas explosively, again forcing mixing/embedding of the agent in the feces. Other compositions and gas-evolving or releasing systems are contemplated and are included in the scope of this invention.

The article of the present invention may also include a responsive system comprising a sensor 66, actuator 67, and stored energy employed to transport the FMA to the feces, mix the agent with the feces, or cause the agent to be expressed to contact the feces. One preferred embodiment comprises a shaped, compressed, macro-porous foam 68, such as a reticulated polyurethane foam available as PG14848T20, and having 20 pores per square inch, from PCF Foam Corporation of Hamilton, OH, held in compression under a water-soluble polyvinyl alcohol film as shown in Figure 8. The foam 68 additionally comprises an FMA 75. Contact with fecal water results in dissolution of at least a portion of the PVA film resulting in a release of the stored mechanical energy in the foam 68 and mechanical transport of

the agent toward and into the fecal mass. In certain embodiments, mixing may occur via a mechanism incorporated in the article as described above (e.g., responsive system), mechanical action from the wearer's weight and/or motion, and/or the flow of feces during or subsequent to the act of defecation (especially low viscosity feces) to facilitate treatment of a greater proportion of the fecal mass. Other responsive systems are described in detail in co-pending U.S. patent application Serial No. 09/106,424 entitled "Disposable Article Having A Discontinuous Responsive System" (P&G Case 7197) filed in the names of Roe et al. on June 29, 1998; which is hereby incorporated by reference herein.

In alternative embodiments, the FMA may be disposed on or associated with three-dimensional structures joined to or separate from other elements of the absorbent article. For example, the absorbent article may include an element with protrusions, bumps, loops or the like which help make the FMA available to contact the feces. In one preferred embodiment, "hairs" or strands of a hot melt resin including the feces modifying agent may be printed on a substrate 82. (An example of a substrate including hairs comprising an FMA is shown in Figure 7.) The agent may be incorporated into the resin such that it moves to the surface of the hairs and is available to the feces. Alternatively, the agent may be releasably bonded to the hairs via any of the techniques described above. Examples of suitable hairs and hooks are described in more detail in U.S. Pat. No. 5,058,247 issued to Thomas et al. on October 22, 1991; U.S. Pat. No. 5,116,563 issued to Thomas et al. on May 26, 1992; U.S. Pat. No. 5,326,415 issued to Thomas et al. on July 5, 1994; and U.S. Pat. No. 5,762,645 issued to Peck et al. on June 9, 1998. Each of these patents is incorporated by reference herein.

In yet another embodiment, the FMA may be delivered to the feces and/or skin via a brush structure 60, one example of which is shown in Figure 6. A brush structure may include a multiplicity of substantially aligned strands, fibers, twisted yarns, strings, or other filamentous materials affixed to a substrate. The substrate may be planar, curved, ribbon-like, or have compound curvature and may be porous or non-porous. The brush filaments 62 are preferably bendable under the forces exerted by the feces during excretion so as to allow feces to readily pass through or

between the filaments 62. The brush filaments 62 may be permanently or releasably affixed to the substrate. The filaments 62 may be of plant or animal origin (e.g., cotton, etc.), cellulosic or synthetic and may have different or similar lengths. The FMA is releasably affixed to the filaments 62 of the brush structure 60 such that as the feces is pushed past the brush filaments 62, the agent is released and mixed with the feces. The brush structure 60 may be integral with the article or may be separately applied to the wearer's perianal region and may optionally comprise adhesive or other joining means for adhering to the wearer or the article. The brush structure 60 may be mounted over a spacer (as described above) having a void under the filaments 62 so as to provide a space for the treated feces to occupy.

The FMAs may also be delivered via the use of "smart" gels that undergo a phase transition or a geometric or volume change in response to certain changes in pH, water content and/or some other trigger. Shape memory materials (i.e., metal alloys or plastics that return to a pre-set geometry or shape when the temperature reaches a pre-determined threshold) may also be employed to move the agent into position to contact or mix with feces, given the appropriate temperature change. Additionally, swellable materials, such as superabsorbent polymers or foams, may be used to promote feces contact with the FMA. As a structure containing such swellable materials imbibes water, whether from feces or urine, it may transport a FMA associated with the body-facing surface of the structure toward a fecal mass and/or promote mixing with the feces. Foam-forming materials may also transport the FMA and promote contact with feces in the article. In this case, the foam forming material comprises the FMA (or is associated with the agent) and coats the fecal mass as the foam is generated and its volume increases.

The FMAs may also be held on or within macro-particulate elements 170, as described below. These macro-particulate elements 170 may be contained in a waste management element 120, attached to a topsheet, cuff, or other feature of the article (releasably or not), or loose in a separate article attached independently to the body. Some exemplary macro-particulate structures are shown in Figures 2-4. Further, any of the structures that hold, carry, deliver, or mix the FMA may comprise protrusions

or other three-dimensional geometries designed to increase contact area of the FMA and the feces and/or to promote mixing.

In preferred embodiments, the FMA is associated with the topsheet of the absorbent structure or article. However, the FMA may be associated with a layer underneath the topsheet, such as an acquisition layer. In embodiments where the FMA is disposed in a layer underneath a topsheet, such as in a waste management element 120, feces must readily penetrate the topsheet, sublayer, and any other overlying structure for the agent to be available in an effective amount. Thus, it is preferred that such structures have an Acceptance Under Pressure of at least about 0.50 g/cm²/J, and preferably at least about 1.0 g/cm²/J, as described in the Test Methods section below. In any case the agent is preferably located near the region of the article generally associated with the wearer's perianal region.

As shown in Figure 2, the present invention may include a waste management element 120. The waste management element 120 is designed to help manage the acceptance, storage and/or immobilization of the viscous fluid bodily waste. The waste management element 120 can be located anywhere in the article, including the crotch region or either waist region, or may be associated with or be included in any structure or element such as the core 28, a leg cuff, etc. In preferred embodiments, the waste management element 120 is located in the region of the article that is near the wearer's perianal region when worn. This helps ensure that any waste discharged is deposited on or near the waste management element 120.

Although structures which accept, store and immobilize viscous fluid bodily wastes are preferred, in certain embodiments of the present invention, the waste management element 120 may comprise only an acceptance element, a storage element or an immobilization element, or may include a combination of two of the elements, but not the third. Also, in certain embodiments, one element may perform more than one function (e.g., a storage element may perform both the storage and immobilization functions). For example, the absorbent article of the present invention may include an acceptance and a storage element to manage viscous fluid bodily wastes without a separate immobilization element, per se.

The acceptance element 150 may be any material or structure capable of accepting bodily exudates. (As used herein, the term "accept" or "acceptance" refers to the penetration of a structure by materials deposited thereon. Penetration is defined by the passage of materials through the surface of the structure upon which the material was deposited. Penetration of nonuniform structures can be defined as the passage of a material through a plane defining the surface upon which the material was deposited.) The acceptance element 150 may include a single material or a number of materials operatively associated with each other. Further, the acceptance element 150 may be integral with another element of the diaper 20 or may be one or more separate elements joined directly or indirectly with one or more elements of the diaper 20. Further, any or all of the acceptance element 150 may be removable from the absorbent article for separate disposal, if desirable.

The acceptance element 150 is preferably disposed at least partially in the crotch region 37 of the diaper 20 adjacent the body surface 47 of the core 28, although in some alternate embodiments, the acceptance element 150 may include at least a portion of a leg cuff, waistband, fecal waste containment pocket, or the like, or may be operatively associated with any such features. Preferably, at least the portion of the acceptance element 150 located in the region of diaper 20 which is near the anus of the wearer during use is unobstructed by overlying layers of structures, such as the topsheet 24. Thus, it may be desirable to cut out a portion of the topsheet 24 in the region of the article intended to be located near the wearer's anus and to provide an acceptance element 150 as the body-side liner in that region. Alternatively, any or all of the topsheet 24 may be made or treated to act as the acceptance element 150. In one embodiment, as shown in Figure 2, the acceptance element 150 includes at least a portion of the topsheet 24. In other embodiments, the acceptance element 150 may include at least a portion of other elements of the diaper such as the absorbent core 28 or the storage element (described below).

In some embodiments, it may be desirable to provide the diaper 20 with different acceptance capability in different portions of the diaper. This may be accomplished by providing different acceptance elements in the different regions of the diaper 20 or by providing a single acceptance element 150 which has been

manufactured or treated to have regions of differing acceptance characteristics. Further, the acceptance element 150 may be elevated above the plane of the body-facing surface of the article so as to be in better control of exuded viscous fluid bodily wastes. In some embodiments, it may even be desirable to have the acceptance element 150 in contact with skin of wearer in proximity of the viscous bodily waste source (e.g., the perianal region).

Suitable materials and structures for use as the acceptance element 150 may be absorbent or nonabsorbent and may include apertured nonwoven webs, apertured films, apertured formed films, scrims, woven webs, scrim, netting, macroporous thin foams, and the like. One particularly preferred material is a woven nylon netting having a basis weight of about 27.3 g/m^2 , an effective open area of about 60% and a primary aperture size of about 5.0 mm^2 (effective open area and primary aperture size are measured as described in U.S. Patent No. 5,342,338, which is hereby incorporated by reference herein). One such material is available as a Toy Tub Bag from Dollar Tree Dist., of Norfolk, VA. Further, the acceptance element 150, or any portion thereof, may be coated with a lotion or other known substances to add, enhance or change the performance or other characteristics of the element. For example, the acceptance element 150 may be hydrophobic or hydrophilic or treated to be either.

As described above, the FMA may be associated with the acceptance element preferably in the wearer's perianal region. In certain preferred embodiments, the FMA is releasably attached to the acceptance element by the means described above. In alternative embodiments, the agent is releasably encapsulated in a structure associated with at least a portion of the acceptance element 150. The agent may be released to the feces upon contact with water, heat, or pressure/wearer motion. The agent may alternatively first be transferred to the wearer's skin or another portion of the article (e.g., leg cuff) prior to deposition onto the feces. For example, urine may effect the release of a releasably encapsulated agent or composition. The agent may transfer to the wearer's skin by body contact and/or pressure. Upon subsequent contact with feces, the agent will transfer from the skin to the surface of the feces.

Once viscous bodily waste has penetrated the waste management element 120, it is desirable to store or hold the waste away from the wearer during the remainder of the wearing cycle and away from the caregiver during the changing process. As used herein, the term "store" refers to the physical separation of material deposited in a diaper from the body-facing surface of the article such that the material deposited in the diaper is not immediately in contact with or accessible to the wearer's skin. Adequate storage capacity is essential to reduce the probability of leakage and the area of skin contaminated by viscous bodily waste because viscous bodily waste that has been stored is less likely to be available to the body-facing surface of the structure for leakage and migration within the article.

The storage element 152 may be located anywhere in the diaper 20. However, it is preferred that the storage element 152 be operatively associated with the acceptance element 150 and/or topsheet 24, if any, such that viscous bodily waste accepted by the acceptance element 150 may enter the storage element 152. (Embodiments are contemplated wherein the diaper 20 has no topsheet 24 or acceptance element 150. In such cases, the bodily waste may enter the storage element 152 directly, without passing through any overlying structure.) In any case, it is preferred that the storage element 152 be located in the region of the diaper 20 which is located near the wearer's anus when the diaper 20 is worn. Accordingly, it is preferred that at least a portion of the storage element 152 be disposed in the crotch region 37 of the absorbent article. However, in some alternate embodiments, the storage element 152 may include at least a portion of either waist region, a leg cuff, the waistband, a fecal waste containment pocket, or the like, or may be operatively associated with any such features. Further, the storage element 152 may be elevated above the plane of body-facing surface of the article so as to be in better control of exuded viscous bodily wastes. In some embodiments, it may even be desirable to have the storage element 152 in contact with skin of wearer in proximity of the viscous bodily waste source (e.g., the perianal region).

The storage capability of the storage element 152 may be uniform or may vary throughout the diaper 20. Such variations may be accomplished by employing multiple storage elements 152 in the diaper 20 or by providing a single storage

element 152 with regions of different storage properties. Further, any or all of the storage element 152 may be removable from the absorbent article for separate disposal, if desired.

The storage element 152 may be any material or structure capable of storing bodily exudates, as described above. Thus, the storage element 152 may include a single material or a number of materials operatively associated with each other. Further, the storage element 152 may be integral with another element of the diaper 20 or may be one or more separate elements joined directly or indirectly with one or more elements of the diaper 20. In one embodiment, as shown in Figure 2, the storage element 152 includes a structure that is separate from the core 28. However, embodiments are contemplated wherein the storage element 152 includes at least a portion of the core 28.

Suitable materials for use as the storage element 152 may include large cell open foams, macro-porous compression resistant nonwoven highlofts, large size particulate forms of open and closed cell foams (macro and/or microporous), highloft nonwovens, polyolefin, polystyrene, polyurethane foams or particles, structures comprising a multiplicity of vertically oriented looped strands of fibers, absorbent core structures described above having punched holes or depressions, and the like. (As used herein, the term "microporous" refers to materials which are capable of transporting fluids by capillary action. The term "macroporous" refers to materials having pores too large to effect capillary transport of fluid, generally having pores greater than about 0.5 mm in diameter and more specifically, having pores greater than about 1.0 mm in diameter.) One embodiment includes a mechanical fastening loop landing element, having an uncompressed thickness of about 1.5 millimeters available as XPL-7124 from the 3M Corporation of Minneapolis, Minnesota. Another embodiment includes a 6 denier, crimped and resin-bonded nonwoven highloft having a basis weight of 110 grams per square meter and an uncompressed thickness of 7.9 millimeters which is available from the Glit Company of Wrens, Georgia. The storage element 152, or any portion thereof, may include or be coated with a lotion or other known substances to add, enhance or change the performance or other characteristics of the element.

An alternate embodiment of a storage element 152 includes a macro-particulate structure 170 comprising a multiplicity of discrete particles 172, nonlimiting examples of which are shown as Figures 2-4. The macro particles 172 preferably have a nominal size, preferably between about 1.0 mm and about 25.4 mm, and more preferably between about 2 mm and about 16 mm. However, particles as small as 0.5 mm and smaller, and particles larger than about 25.4 mm are contemplated. Particles having a nominal size of about 1.0 mm or greater are those which are generally retained on the surface of a U.S. Standard No. 18 mesh sieve screen. Particles having a nominal size of less than about 25.4 mm are those which generally pass through a U.S. Standard 25.4 mm sieve screen. Particles having a nominal size of 16 mm or greater are those which are generally retained on the surface of a U.S. Standard No. 16 mm sieve screen. The nominal particle size is measured prior to incorporating the particles into a storage element 152 for testing or use. Particles having a nominal size of 8 mm or greater are those which are generally retained on the surface of a U.S. Standard 8 mm sieve screen.

The macro-particulate structure 170 may include any number of particles 172. Further, the particles 172 may be unjoined and free to move within the structure 170 or may be joined to each other by any known means. Alternatively, the structure 170 may include an external support, such as a meltblown hot-melt glue, a web, a netting, a scrim, a thread or other adhesive or nonadhesive entangling supports. Any of the particles 172 may also be joined with any other portion of the diaper structure, such as the topsheet or the core. The particles 172 may also be constrained in patterned, three-dimensional regions such as pleats, "pillows", and pockets.

The individual particles 172 may be made from any material suitable for use in absorbent articles, including the materials described above with regard to the absorbent core 28 or the storage element 152. The materials used in the particles 172 may be absorbent, nonabsorbent, microporous, macroporous, resilient, nonresilient, etc. or may have any other desirable characteristic. Examples of macroporous absorbent materials suitable for use in the particles 172 include highloft nonwovens, open cell foams, bundles of fibers, sponges and the like. Other absorbent materials include cellulosic batts, capillary channel fibers, osmotic storage materials such as

superabsorbent polymers, etc. Nonabsorbent particles 172 may comprise plastic, metal, ceramic, glass, closed cell foams, column packing materials, synthetic fibers, gels, encapsulated gas, liquids and the like. Further, any or all of the particles 172 may include odor absorbents, lotions, skin care formulations, antimicrobials, pH buffers, enzyme inhibitors, and the like.

The storage element 152 may comprise a single type of particle 172 (size, shape, material, etc.) or may include a mixture of different particles 172. The mixture may be homogeneous; heterogeneous, as when particles 172 having different properties are disposed in certain areas of the storage element 152; layered; or any other desirable configuration. In some embodiments, more than one type of mixture may be employed (e.g., macroporous and nonabsorbent particles 172 may be homogeneously mixed in one layer while another layer includes only absorbent particles.) Different layers of particles may be directly adjacent each other or may be separated by one or more materials, such as netting, scrim, nonwoven or woven webs, film, foam, adhesive, and the like.

The macro-particulate structure 170 preferably includes a continuous interstitial void space 174 that is defined by the space between the particles 172. By varying the size and/or shape of the particles 172, the interstitial void space 174 can be controlled. The particles may be of any known shape, including spheres, oblate spheroids, rectangular and polygonal solids, and the like.

In addition to its storage function, the storage element 152 may transport viscous bodily waste within the absorbent article 20 in directions generally parallel to the plane of the backsheet 26. The transport may be active, such that capillary or other forces result in the movement of the viscous bodily waste or components thereof (e.g., free water). In other embodiments, the transport may be passive whereby viscous fluid bodily waste or components thereof move through the structure under the influence of externally applied forces, such as gravity, wearer pressure or wearer motion. In the case of passive transport, the storage element 152 should have relatively large, interconnected channels, or the like, such that the viscous bodily waste may readily move through the structure with minimum energy input.

The FMA of the present invention may be associated with any portion of the storage element 152, including the macro-particulate structures. In certain preferred embodiments wherein the storage element 152 has raised regions, the FMA is associated with the raised regions of the element. Viscous bodily waste penetrating the acceptance element may contact the FMA and carry it to the "lower" regions of the storage element 152, providing enhanced mixing. For example, the raised tops of loop type storage elements may be slightly wetted or dampened and subsequently contacted with the FMA to releasably affix the FMA to the raised portions, and subsequently dried. The releasable attachment may also be effected via water soluble adhesives. In macro-particulate embodiments, the agent may be held within a macro-porous particle. In alternate embodiments, the agent may be releasably affixed to the exterior surface of the particulate elements. Fecal contact with the FMA preferably effects a release of the agent from the storage element and allows mixing with the feces.

Viscous bodily waste that is accepted by, or penetrates, the absorbent article is preferably also retained in the diaper away from the wearer. One preferred way to retain bodily waste, especially viscous bodily waste, is to immobilize the waste in a location away from the wearer. As used herein, the term "immobilize" refers to the ability of the material or structure to retain stored viscous bodily waste under an applied pressure and/or the influence of gravitational forces.

The immobilization element 154 may be any material or structure capable of reducing the proclivity of viscous bodily waste that has penetrated the immobilization element 154 from leaving the structure. Thus, the immobilization element 154 may include a single material or a number of materials operatively associated with each other. Further, the immobilization element 154 may be integral with another element of the diaper 20 or may be one or more separate elements joined directly or indirectly with one or more elements of the diaper 20. For example, the immobilization element 154 may be an unjoined layer of material disposed under the storage element 152 or may include all or a portion of the storage element 152 which is able to immobilize and retain viscous bodily waste, as described above. In any case, it is preferred that the immobilization element 154 be operatively associated with the

storage element 152 and the acceptance element 150. This is necessary to ensure that viscous bodily waste accepted and/ or stored by the article passes into or comes in contact with the immobilization element 154. Accordingly, it may be desirable to locate the immobilization element 154 below the storage element 152 and the acceptance element 150, in at least a portion of the crotch region 37 of the article. However, as noted above if the storage element 152 has transportation capabilities, the immobilization element 154 may be located anywhere in the diaper 20 such that the viscous fluid bodily waste accepted and/or stored can be transported to the immobilization element 154. Further, as with the acceptance and storage elements 150 and 152, the diaper 20 may have uniform or nonuniform immobilization capability. Thus, one or more immobilization elements 154 may incorporated in the article having regions of different immobilization and/or retention performance. Further, any or all of the immobilization element 154 may be removable from the absorbent article for separate disposal, if desirable.

Suitable materials for use in the immobilization element 154 include microporous foams, superabsorbent polymer particles or fibers, cellulosic fibers, capillary channel fibers, entangled synthetic fiber batts and the like. Some preferred materials include foam absorbent materials such as those described in U.S. Pat. Nos. 5,260,345; 5,387,207; and 5,625,222. Other preferred materials include absorbent gelling materials such as those described in U.S. Pat. No. 5,147,345 entitled "High Efficiency Absorbent Articles For Incontinence Management" issued to Young et al. on September 15, 1992. Each of these patents is hereby incorporated by reference herein.

The FMA may be associated with the immobilization element 154. In these embodiments, the modifying agent may act to enhance the efficacy and efficiency of the immobilization element 154 by facilitating the removal of water from the feces, and thereby increasing the speed of the immobilization process and/or reducing the final mobility of the remaining solid fraction of feces. The FMA may alternatively serve to increase the viscosity of the feces within the immobilization via a direct thickening mechanism. The FMA may be loosely associated with the immobilization

element or may be releasably affixed (i.e., such that feces water may effect its release) to the immobilization element 154.

The article of the present invention can also improve the removability of feces or other bodily exudates from the wearer's skin, and hence enhance the efficacy of skin cleanup after excretion. Generally, feces that are very soft or liquid (i.e., have low Hardness values) are relatively easy to remove from the skin since they have low viscosities and high water content. Feces having high Hardness values (i.e., are solid) are also relatively easy to remove since, being solid-like, they do not adhere aggressively to the skin. Pasty feces (i.e., those having intermediate Hardness values, often in the range of about 25 to about 800 grams), however, are relatively difficult to remove from the skin.

As used herein, "pasty feces" refers to a relatively wide range of consistency generally characterized by a lack of spontaneous flow under gravitational forces, but a readily plastic flow response to pressures similar to those applied by a baby sitting on a diaper, and is closely represented by Analog B and Fluorescing Analog B, as described herein, which is used in the cleaning efficacy measurements described below. Pasty feces is generally difficult to remove from the skin of a wearer because the internal cohesive force is lower than the adhesion force of the pasty feces to skin. This results in a "shearing" effect (i.e., the feces fails cohesively, leaving the remaining feces on the skin) when the caregiver attempts to remove the feces, such as with a disposable wet wipe. This forces the caregiver to repeat the wiping process in order to effect a more complete cleaning. In the case of baby diapers, most parents will continue to wipe until no visible residue can be seen either on the baby's skin or the last wipe used. This process can be quite tedious and time-consuming and may require the use of a large number of wipes, increasing the cost of the cleanup. Additionally, it has been found that residual, invisible, "micro-level" contamination, as detected by residual fecal enzymes and coliform bacteria, remains on virtually all babies following a feces cleanup. Measurable residual fecal contamination has been found on babies' skin after cleanup with various cleaning protocols and aids, including disposable wet wipes, wetted paper towels and cotton balls, and baths with water and/or soap. The residual fecal contamination generally comprises all or most

of the components of feces, including enzymes (e.g., trypsin, chymotrypsin, leucine aminopeptidase, and lipase), bile salts, and microorganisms (e.g., *Candida albicans* and fecal coliforms including *E. coli*), many of which are implicated in skin irritation such as redness, diaper dermatitis, and *Candidiasis*. Further, high levels of residual fecal contamination have been found in irritated areas of diapered skin. It is highly desirable to provide an enhanced level of feces removability from the skin so as to obtain skin health, convenience, and cost benefits.

Modifying pasty feces by either significantly increasing or decreasing its hardness, for example by employing FMAs in the receiving article as heretofore described, will generally result in improved feces removability and enhanced cleaning efficacy. The article also preferably includes a lotion or other skin care composition, either separately or as a carrier for the FMA, disposed on an element or elements of the article that may contact the wearer's skin and effect transfer of at least a portion of the lotion or other skin care composition to the skin, such transfer ideally occurring prior to elimination of bodily waste. For example, in regard to a diaper, incontinence brief, or sanitary napkin, the lotion or other skin care composition would preferably be disposed on a portion of the topsheet, cuff, waste receiving pocket (if present), or other element in the crotch region of the article so as to be located near and transfer to the perianal region of the wearer. Examples of suitable lotions and other skin care compositions are described herein.

An *in vitro* test method, described in detail in the Test Methods section below, has been developed to simulate macro and microlevel feces removability in the context of a cleaning regimen. Feces removability may be characterized in terms of the degree or amount of residual feces on the wearer's skin (i.e., residual contamination). An enhanced level of removability results in, and may be quantified by, a reduction in the level, including area and/or mass of residual fecal contamination. The test employs a synthetic fecal analog having viscous, elastic, and adhesion properties representative of actual infant pasty feces. The test additionally includes a fluorescent marker incorporated into the fecal analog, a synthetic skin analog, and a wiping device. Feces remaining on the skin analog after a defined wiping protocol is reported in terms of the area and intensity (i.e., the relative amount

of residual fecal analog per unit area of skin) of the fluorescence on the skin analog under a ultraviolet light. As used herein, the term "Waste Contamination Area" refers to the contaminated area of the skin analog measured after the defined wiping protocol. As further used herein, the term "Waste Contamination Mass" refers to the relative mass of feces remaining on the skin analog, calculated using "Waste Contamination Area" and the amount of residual feces per unit area of skin (i.e., as measured by the ultraviolet light intensity data). Exemplary data are presented in Table VIII.

Preferred disposable articles of the present invention include one or more compositions which enhance the removability of feces from the skin as determined by a Waste Contamination Area of less than about 15 cm^2 . More preferred disposable articles of the invention include one or more compositions which enhance the removability of feces from the skin as determined by a Waste Contamination Area of less than about 12 cm^2 . Even more preferred disposable articles of the invention include one or more compositions which enhance the removability of feces from the skin as determined by a Waste Contamination Area of less than about 10 cm^2 .

Preferred disposable articles of the present invention include one or more compositions which enhance the removability of feces from the skin resulting in a Waste Contamination Mass of less than about 14 mass units. More preferably, the disposable article include one or more compositions which provide enhanced removability of feces from the skin resulting in a Waste Contamination Mass of no less than about 10 mass units. Even more preferably, the disposable article include one or more compositions which provide an enhanced removability of feces from the skin resulting in a Waste Contamination Mass of less than about 8 mass units.

The improvement in feces removability (which relates to the effectiveness of the article in enhancing the cleanability of feces from the wearer's skin and the reduction in residual contamination) is illustrated with several examples in Table VIII below. The lotion composition referenced in Table VIII may be prepared in accord with Example 5 of U.S. Patent 5,643,588, varying the weight percentage/constituents of the lotion composition to be consistent with those described in Table VIII.

TABLE VIII

Skin Analog Treatment	Waste Contamination Area (cm ²)	Waste Contamination Mass (mass units)
<u>Comparative Examples</u>		
(A) No treatment	27.5	27.3
(B) lotion (57% petrolatum, 42% stearyl alcohol, 1% aloe extract - see above)	28.0	27.7
(C) Johnson's Baby Powder (see Table II above)	18.6	17.1
(D) Johnson's Baby Powder (see Table II above) plus lotion (57% petrolatum, 42% stearyl alcohol, 1% aloe extract)	21.1	19.2
<u>Examples of the Present Invention</u>		
(E) FMA (alginic acid, Ca-ammonium salt - see Table VI above) plus lotion (57% petrolatum, 42% stearyl alcohol, 1% aloe extract)	7.4	6.7
(F) FMA (alginic acid, Ca-ammonium salt - see Table VI above) without lotion	10.1	9.0
(G) FMA (carboxymethyl cellulose - see Table V above) without lotion	7.9	7.3

As can be readily seen above in Table VIII, a lotion composition and baby powder provide at best only a modest removability/cleaning benefit versus an untreated skin. On the other hand, in Example (E) wherein the article delivers an FMA composition to the feces and/or skin in addition to the lotion composition, a much more significant and unexpected benefit level was achieved. This simulates a skin care composition

such as a lotion transferred to the wearer's skin by, for example, a topsheet comprising a lotion, as described herein, applied to the wearer-facing side of the topsheet and a subsequent release, whether instantaneously or over an extended period of time, of an FMA to contact the feces and surrounding skin area. Examples (F) and (G) of Table VIII illustrate that the benefits of the invention may also be obtained through the use of FMA compositions without lotion.

Preferred Embodiments

As noted above, the present invention is applicable to many types of absorbent articles such as diapers, training pants, incontinence briefs, incontinence undergarments or pads, inserts including absorbent inserts, diaper holders and liners, feminine hygiene garments, wipes, disposable mops, bandages and the like and separate articles attached to a wearer over the perianal region such as colostomy bags. Thus, the following examples of preferred embodiments of the present invention should not construed to limit the scope of the invention.

One preferred embodiment of the present invention is the absorbent article, in the form of diaper 20, illustrated in Figure 2. The diaper 20 has a first waist region 36, a second waist region 38 and a crotch region 37 located between the first waist region 36 and the second waist region 38. The diaper 20 includes a topsheet 24, a backsheet 26 and an absorbent core 28 disposed between the topsheet 24 and the backsheet 26. The topsheet 24 is disposed in at least a portion of the first waist region 36 adjacent the body facing surface 47 of the core 28. The diaper 20 also includes an acceptance element 150 joined with the topsheet 24 and extending longitudinally away from the topsheet 24 through at least a portion of the crotch region 37 and at least a portion of the second waist region 38. The acceptance element 150 includes a woven netting available as a Tub Toy Bag from Dollar Tree Dist., of Norfolk, VA.

The diaper 20 preferably further includes a storage element 152 located between the acceptance element 150 and the backsheet 26. The storage element 152 is located in at least a portion of the crotch region 37 and at least a portion of the second waist region 38. In this embodiment, the storage element 152 includes a

macro-particulate structure 170 comprising particles 172. Specifically, the macro-particulate structure 170 includes about two grams of the scrubber particles mixed with about 0.35 grams of strips of foam absorbent material having a basis weight of 45 grams per square meter, as described in U.S. Pat. No. 5,260,345. (The scrubber particles can be made by cutting the abrasive nonwoven highloft side of a scrubbing pad (e.g., available as Light Duty Scrubbers #00065 from the Libman Company of Arcola, IL) into particles of about 8 mm x about 7 mm x about 5 mm.) The strips have dimensions of about 19 millimeters in length, 6.4 millimeters in width, and 2 millimeters in thickness. The scrubber particles are distributed over a 2.5 inch x 6.4 inch (16 square inch) area disposed along the longitudinal axis of the article of approximately 0.8 mm thick "thin until wet" foam absorbent material (described in U.S. Pat. No. 5,387,207 which is incorporated herein by reference) having a basis weight of 126 grams per square meter. The scrubber particles are relatively homogeneously mixed with the absorbent foam strips and are free to move within the area circumscribed by the layer of "thin-until-wet" absorbent foam material. The particles and strips are preferably not bonded to the woven netting topsheet or any other layer. A FMA is preferably associated with the particulate elements of the storage layer via any of the means described herein. The acceptance element 150 is bonded to the underlying layers outside the periphery of the layer of "thin-until-wet" absorbent foam.

Another preferred embodiment of the present invention is the absorbent article, in the form of diaper 200, illustrated in Figure 11. The wearer-facing surface of the topsheet of this embodiment comprises the lotion composition (57% petrolatum, 42% stearyl alcohol, 1% aloe extract) referenced above in Table VIII. Lotion 186 may be applied to the topsheet 24 as described in connection with Example 5 of U.S. Patent No. 5,643,588, referenced herein relative to lotioned topsheets, and which is incorporated herein by reference.

As shown in Figures 11 and 12, the diaper 200 also includes an effective amount (about 3.5 grams) of an alginic acid, ammonium-calcium salt composition 190 (Sigma A-7253, available from Sigma Chemical Co., St. Louis, Missouri), described above in connection with Tables VI and VIII as an FMA, applied to a

carrier 180. Carrier 180 comprises a wearer-facing fibrous loop material 182 which may be bonded to an optional thermoplastic backing 184 made, for example, from polypropylene. Materials of this nature are described in PCT Patent Application Serial No. US97/20840 entitled "Disposable Absorbent Article Having Fecal Management Member", filed November 14, 1997, corresponding to U.S. Application Serial No. _____, filed _____ (P&G Case CM1642FQ), which is incorporated herein by reference. The alginic acid, ammonium-calcium salt 190 is releasably affixed to a loop material 182 via hydrogen bonding. Such hydrogen bonding may be obtained by applying a fine water mist to the wearer-facing surface of the loop material, applying the alginic acid, ammonium-calcium salt to the wearer-facing surface, and subsequently drying the structure. Excess or additional alginic acid, ammonium-calcium salt may be disposed in any voids 185 in the loop material 182. Carrier 180 is joined to the wearer-facing surface of the topsheet 24 in at least a portion of the crotch region associated with the wearer's perianal region using adhesive, or any other suitable attachment means or combinations of means such as heat bonds, pressure bonds, ultrasonic bonds, dynamic mechanical bonds. Lotion composition 188 may also be applied to at least a portion of the carrier, such as to the valleys 186 between loops in loop material 182.

In yet another embodiment, the alginic acid, ammonium-calcium salt is encapsulated in a sealed envelope, at least a portion of the body-facing side of which comprises a soluble film (e.g., MONOSOL 7031, described above). The envelope containing the alginic acid salt may be affixed to the topsheet surface of the foregoing diaper example or may be disposed under a portion of the topsheet 24 comprising apertures of sufficient size (e.g., at least about 1 mm in their longest dimension). Water (from a urination, for example) or another constituent of a body exudate will dissolve at least a portion of the soluble region of the envelope, releasing the alginic acid to the wearer-facing side of the topsheet 24, and subsequently to the skin and/or feces. Alternatively, the alginic acid, ammonium-calcium salt (or other FMA composition)/carrier structure may include a responsive system as described in more detail above comprising a compressed resilient element (e.g., a macroporous foam or a high internal phase emulsion foam as described in the above-referenced U.S.

Patents Nos. 5,260,345 and 5,625,222) comprising the FMA held at or near the wearer-facing side of said resilient element under vacuum in a bag, at least a portion of which comprises a soluble film (e.g., MONOSOL 7031). Upon contact with water (e.g., in urine), the soluble film will dissolve, releasing the vacuum and allowing the compressed resilient element to expand and deliver the FMA to the skin and/or feces.

In still another embodiment, as shown in Figure 5, the absorbent article of the invention may be an insert 21, a sanitary napkin, or other absorbent article which is intended to be applied separately to the wearer or to be placed in the wearer's underwear, an outer cover or the like. Thus, the insert 21 is generally not intended to take the form of a pant, but rather is to be used in conjunction with a pant or other structure which holds the insert 21 in place about the wearer. The absorbent insert 21 has a pair of opposed end regions 135 separated by a central region 137 and includes an absorbent assembly 27 which may include an absorbent core 28, an acceptance element 150, a storage element 152, an immobilization element 154 and/or the alginic acid, ammonium-calcium salt/loop carrier structure as described above. The attachment element 41 may comprise adhesive, cohesive, hooks, snaps, buckles, buttons, ties, magnetic, electronic and/or any other known means for attaching absorbent articles to undergarments.

TEST METHODS

Viscosity

The viscosity may be determined by a controlled stress rheometer. A suitable rheometer is available from T. A. Instruments, Inc. of New Castle, DE, as model number SC²100. The rheometer utilizes a stainless steel parallel plate fixture. The rheometer has a rigid horizontal first plate onto which the sample is placed and a second plate mounted over the first plate such that the axis of said second plate is perpendicular to the first plate. The second plate is 2 or 4 centimeters in diameter. A two centimeter (2 cm) parallel plate is used for firm, pasty, or highly mucous samples, while the four centimeter (4 cm) parallel plate is used for very runny or "water-like" fecal samples. The first and second plates are spaced apart up to 2000

microns during the measurement process. The second plate is connected to a drive shaft for axial rotation. The drive motor and strain sensor are also mounted on the drive shaft.

A suitable sample (typically 2 to 3 grams) of an analog to be tested is centered on the first plate and generally centered beneath the axis of the second plate. Prior to the test, any large pieces of undigested food material (e.g., seeds) are removed. The first plate is raised into position. Excess amounts of the sample which are displaced beyond the diameter of the second plate are removed using a spatula. Water is then misted around the edges of the sample to prevent edge effects due to moisture loss during the measurement process. A programmed application of a shear stress, from 50 to 50,000 dynes/cm² for pasty and firm samples, is applied to the sample by the rheometer. For runny and watery samples, a shear stress range of 5 to 5000 dynes/cm² was used instead. The data is fitted to a power law function where the apparent viscosity = $k j^{(n-1)}$, k = consistency (units of cP x sec⁽ⁿ⁻¹⁾), j = shear rate (Units of 1/sec), and n = shear index (dimensionless). Therefore, when j = one 1/sec, the viscosity = k . (The plates are maintained at 35 degrees C throughout the test.)

Hardness Method

Hardness is measured using a Stevens-Farnell QTS-25 Texture Analyzer, model 7113-5kg, and associated software on an Intel-based machine having a 486 processor or higher. A ½ inch stainless steel spherical probe and an analog receptacle are provided. A suitable probe is the TA18 probe available from Leonard Farnell Co. of Hatfield, England. The analog receptacle can be made by cutting a 7 milliliter linear low density polyethylene scintillation vial (having an inside diameter of 0.55 inches +/- 0.005 inches) to about 16 millimeter length. Suitable vials are available from Kimble Glass Company of Vineland, New Jersey as #58503-7 vials. The analog receptacle is filled to the top edge (level) with the analog (Analog A or B, as described below) or feces to be tested. If a modification agent is to be evaluated, the sample is prepared via the Sample Preparation Method described below. The vial is centered under the ½ inch spherical stainless steel probe. The probe is lowered such that it just contacts the surface of the analog in the vial. The probe 162 is

moved downward 7 millimeters at about 100 millimeters per minute and then stopped. The Hardness is the maximum recorded resistive force encountered by the probe on its 7 millimeter stroke. (The temperature of the room and the analog should be between about 65 to 75 degrees Fahrenheit during the course of the measurement.) For reference, Hardness has been found to relate strongly to the complex modulus of the material, which is a combination of the viscous and elastic moduli of the material.

Method for Making Analog A

1.5 grams of Ultra Dawn dishwashing liquid (available from the Procter & Gamble Co, Cincinnati, OH) is added to an empty metal mixing bowl. 10 grams each of Feclone FPS-2 and Feclone FPS-4 are added into the bowl containing the Dawn. (Both Feclone materials are available from Siliclone Studios, Valley Forge, PA.) Then 200 milliliters of distilled water heated to 200°F is added to the mixing bowl. The resultant mixture is then carefully stirred by hand, to avoid introducing air bubbles to the mixture, using a rubber or plastic spatula until homogenous, (usually about 3-5 minutes). If prepared properly, the Analog A will have a Hardness between about 7 and 10 grams as measured by the above Hardness Method.

Method for Making Analog B

5 grams each of FECLONE BFPS-4, FECLONE BFPS-6, and FECLONE BFPS-7 are added into an empty metal mixing bowl. (the FECLONE materials are available from Siliclone Studios, Valley Forge, PA.). Then 0.67 grams of Carbopol 941 (available from the B.F. Goodrich Corp. of Brecksville, OH) is added into the bowl and these four ingredients are stirred until they are homogeneously mixed using a rubber or plastic spatula to ensure adequate dispersion of the powder materials upon mixing in water. Next, 60 milliliters of water heated to 200°F is added to the mixing bowl. The resultant mixture is mixed manually, and is stirred carefully to avoid introducing air bubbles to the mixture, using a rubber or plastic spatula until homogenous (usually about 3-5 minutes). If prepared properly, the Analog B will have a Hardness between about 600 and 650 grams.

Method for Making Fluorescing Analog B

A fluorescing version of analog B to be used in the Waste Contamination Methods below is made by following the procedure described for Analog B above, with the exception that 0.40 grams of a fluorescing agent, Brightener 49 - Tinopal CBS-X, available from Ciba Specialty Chemicals Corp. of High Point, North Carolina, is added to and mixed with the dry FeClone mixture and Carbopol 941 prior to the addition of the water as described in connection with Analog B above.

Method for Making Analog C

Analog C is a fecal material analog made by mixing 10 grams of Carbopol 941 available from the B.F. Goodrich Corporation of Brecksville, OH, or an equivalent acrylic polymer in 900 milliliters of distilled water. The Carbopol 941 and distilled water are weighed and measured separately. A 3-bladed marine-type propeller having a 2 inch diameter paddle, (available from VWR Scientific Products Corp. of Cincinnati, Ohio, Catalog # BR4553-64, affixed to a 3/8" stirring shaft BR4553-52), is used to stir the distilled water. The propeller speed should be constant at 450 rpm during mixing. The mixer should form a vortex without splashing. The Carbopol is slowly sieved into the water so that it is drawn into the vortex and mixed without forming white clumps, or "fish eyes". The mixture is stirred until all of the Carbopol has been added, and then for a period of 2 minutes thereafter. The sides of the bowl containing the mixture should be scraped and the bowl should be rotated as needed to achieve a homogeneous mixture. (The mixture will likely be slightly cloudy with air bubbles). One hundred grams of a 1.0 N volumetric NaOH solution, available from J. T. Baker Co., Phillipsburg, NJ, is then slowly measured into the mixture and the mixture is stirred until homogeneous. The mixture should become thick and clear. The mixture should be stirred for 2 minutes after the addition of the alkali solution. The neutralized mixture should be allowed to equilibrate for at least 12 hours and should be used for the Acceptance Under Pressure test within 96 hours thereafter. Before the Carbopol mixture is used, it should be stirred in the container at low speed (about 50 rpm) for about 1 minute to ensure the mixture is homogeneous.

Analog C should, if prepared correctly, have a "Hardness" value between 55 and 65 grams. Hardness is measured using a Stevens-Farnell QTS-25 Texture Analyzer, model 7113-5kg, and associated software on an Intel-based machine having a 486 processor or higher. A ½ inch stainless steel spherical probe and an analog receptacle are provided. A suitable probe is the TA18 probe available from Leonard Farnell Co. of Hatfield, England. The analog receptacle can be made by cutting a 7 milliliter linear low density polyethylene scintillation vial (having an inside diameter of 0.55 inches +/- 0.005 inches) to a 15 millimeter length. Suitable vials are available from Kimble Glass Company of Vineland, New Jersey as #58503-7 vials.

The analog receptacle is filled to within 2 millimeters of the top edge with the analog to be tested. The vial is centered under the ½ inch spherical stainless steel probe. The probe is lowered to a distance of about 1 millimeter from the surface of the analog in the vial. The probe 162 is moved downward 7 millimeters at 100 millimeters per minute and then stopped. The Hardness is the maximum recorded resistive force encountered by the probe on its 7 millimeter stroke. (The temperature of the room and the analog should be between about 65 to 75 degrees Fahrenheit during the course of the measurement.)

Sample Preparation Method

A 250 mL Precleaned VWRbrand TraceClean jar (VWR # 15900-196) is placed on a balance and tared. The desired amount of chemical agent is measured into the cup and its exact weight is recorded. After the chemical weight is recorded the balance is tared again. The desired amount of feces or fecal analog is measured into the cup containing the chemical agent. The exact amount of feces or fecal analog is recorded and the chemical agent and feces or fecal analog is stirred vigorously using the spatula end of a Standard Ayre Cervi-Scraper (VWR # 15620-009) until homogeneous (total stirring time is generally about 2 minutes). For the purposes of this method, the beginning of the stirring process is defined as t = 0 minutes. After the sample is mixed it is allowed to sit for the remainder of the desired reaction time. For the data presented herein, this reaction time is set at t = three minutes elapsed from the beginning of the stirring process. It is then loaded

into the 16mm receptacle described above in the Hardness Method using the spatula end of a Standard Ayre Crevi-Scraper, and the Hardness test is performed (starting at $t = 3$ min. from the beginning of the stirring process, as described above).

5 Acceptance Under Pressure

Acceptance Under Pressure is measured by the following test which uses the apparatus 139 illustrated in Figure 9. A hollow plexiglas cylinder 140 is provided mounted on a stainless steel plate 142 about 9.5 mm thick. The plate 142 is a square, about 10.16 cm x 10.16 cm (about 4 in. x 4 in.). The cylinder 140 and plate
10 combination has a height of 7.6 centimeters (about 3.0 inches), an inside diameter of 5.08 centimeters (about 2.00 inches) and an outside diameter of 6.3 centimeters (about 2.48 inches). The bottom of the cylinder 140 extends below the plate 142 a distance of about 3.5 millimeters. The lip 143 prevents the test fluid 166 from leaking outside the designated test area. Two 625 gram weights 156 are also
15 provided, each having a diameter of 5.08 cm (about 2.0 inches).

A cylindrically shaped 24.6 gram plexiglas weight 144 is provided. The weight 144 has a diameter of 5.08 centimeters (about 2.0 inches), so that the weight 144 fits with close tolerance within the cylinder 140 but can freely slide throughout the hole 141 in the cylinder 140. This arrangement provides a pressure of about 119 Pascals
20 (Pa) (about 0.017 pounds per square inch) and a test area of about 20.27 square cm (about 3.142 square inches). If desired, the weight 144 may have a handle 145 to allow it to be easily inserted into and removed from the cylinder 140. In such cases, the combined mass of the handle 145 and the cylindrical weight 144 should equal 24.6 grams.

25 A sample 146 of the structure to be tested for Acceptance Under Pressure properties is provided. The sample 146 may be cut from an existing diaper or may be constructed from material which has not been formed into a diaper. The sample 146 includes the entire structure intended for use in an article or the entire structure of the article to be evaluated, including the top layer 161. (In order to measure the
30 Acceptance Under Pressure performance of discrete acceptance elements, as described in the Acceptance Element section above, the Acceptance Under Pressure

test is performed using a standard storage element 147 in place of any underlying structure or layers. The standard storage element 147 used herein includes a 4 inch square 1.6 mm thick aluminum plate having a pattern of 153 regularly spaced 4.3 mm diameter holes 168, as shown in Fig. 10. The holes are arranged such that there are about 26 holes per square inch.) The sample 146 should be cut into a square measuring 10.16 centimeters by 10.16 centimeters (about 4 inches by 4 inches).

Five layers of a high basis weight blotter 149 measuring 4 inches x 4 inches are provided. The top layer 161 of the sample 146 is removed and the remaining components, or layers, of the sample 146 (if there are multiple components or layers) and the five sheets of blotter material 149 are weighed to the nearest 0.01 grams. Thus, if the sample 146 is being taken from a diaper, the layers of the diaper such as topsheets, secondary topsheets, acquisition layers, absorbent cores etc., should be separated prior to weighing. (In some cases, a single layer may comprise two or more permanently bonded components.) In so doing, care must be taken not to destroy the sample 146 or cause unintended gross deformation of any parts of the sample 146. The layers of the sample 146 may be frozen to aid their separation from adjacent layers of the sample 146. Freezing may be accomplished using PH100-15 circuit refrigerant made by Philips ECG, Inc. of Waltham, Massachusetts.

The sample 146 should be reassembled as originally configured on top of 5 stacked layers of blotter material 149 with the side of the sample 146 intended to face the wearer oriented facing up and away from the blotter material 149. The blotter material 149 is preferably filtration grade paper, available from Ahlstrom Filtration, Inc. of Mt. Holly Springs, Pennsylvania as #632-025, having a basis weight of about 90 grams per meter.

The combined assembly of the sample 146 and the blotter material 149 is centered on the work surface 164 of a Stevens-Farnell QTS-25 Model 7113-5kg Texture Analyzer 160 (available from Leonard Farnell Co. of Hatfield, England), under the probe 162. A suitable probe 162 is a 100 cm flat-ended cylindrical aluminum extension rod "QTSM3100" available from the Leonard Farnell Co. of Hatfield England. The cylinder 140 is centered on the sample 146. The two 625 gram weights 156 are placed on opposite corners (diagonally) of the plate 142 to

stabilize it. A syringe having an opening of about 4 to 6 millimeters is used to dispense approximately 10 cubic centimeters of viscous fluid bodily waste analog 166 (Analog C as described below) through the hole 141 in the cylinder 140 onto the top of the sample 146.

5 Once the proper amount of feces analog 166 (Analog C) has been measured into the cylinder 140, the 24.6 gram weight 144 is inserted slowly and gently into the hole 140 in the cylinder 140 until it rests on the surface of the analog, and subsequently gently rotated one rotation clockwise followed by one rotation counter-clockwise, both rotations performed while carefully avoiding the application
10 of any downward force on the weight. The Texture Analyzer 160 is activated so the probe 162 depresses the cylindrical weight 144 at a rate of 10 millimeters per minute until a resisting force of about 144.6 grams is reached. The Texture Analyzer 160 is set to stop the downward stroke once the resistance force of 144.6 grams is reached. The recorder is set to trigger at a resistive force of 5 grams. (The maximum resisting
15 force of 144.6 grams corresponds to an applied pressure of 700 Pascals or 0.1 pounds per square inch). Once a resistive force of 144.6 grams is reached, the probe 162 is retracted to its starting position.

 The weight 144 is removed from the cylinder 140, and then the cylinder 140 is removed from the surface of the sample 146, taking care not to drip any Analog C
20 remaining in the cylinder 140 onto the sample. The top layer 161 of the sample 146 is then removed from the underlying layer(s) of the sample 146 by dragging the top layer 161 parallel to the surface of the underlying layers, if possible taking care not to drip any Analog C onto the blotter paper. For certain structures where the top layer 161 is difficult to remove by dragging parallel to the underlying layers, the top layer
25 161 may be peeled or lifted away from the underlying layers of sample 146. If the sample 146 comprises only a single layer, the standard acceptance element 151, described below, is utilized as the top layer 161 of the sample 146. The underlying layers of the sample 146 and the blotter material 149 are then weighed. The amount of test Analog C accepted by the sample 146 equals the increase in combined weight
30 of the underlying layer(s) of the sample 146 and the blotter material 149 caused by the test Analog C penetrating through the top surface layer of the sample 146 per

unit work performed (in millijoules) on a unit area basis. The area under the force vs. distance curve, used in calculating the unit work, is calculated by integrating the force resisting the probe on its downward stroke over the total distance traveled until the maximum force of 144.6 grams is registered. The unit work is calculated using the following equation:

$$\text{Unit Work (mJ)} = \text{Area under the force vs. distance curve (g/mm)} (9.81 \text{ m/s}^2) / (1000 \text{ mm/m})$$

Waste Contamination Area and Mass Methods

Waste Contamination Area and Mass are determined by the following procedures, certain of the assemblies and apparatus used in the procedures being illustrated in Figures 13 through 20.

Preparation of Skin Assembly

As shown in Figure 13, a skin assembly 201 is prepared from a skin analog 203 and a backing sheet 205. The skin analog is a 10.2 by 12.7 cm (4 by 5 inch) BIOCLUSIVE self-adhesive transparent dressing (hereinafter, BIOCLUSIVE film), available from Johnson & Johnson Medical of Arlington, Texas. The backing sheet is a 15.2 by 20.3 cm (6 by 8 inch) portion cut from black background paper (Epic BLACK CLASSIC linen paper, available from Johnston Paper Company, Cincinnati, Ohio). The skin assembly is formed by carefully removing the outer wrapping and release paper from the BIOCLUSIVE film, centering the film on the backing sheet (with the respective long edges parallel), and then using the film's adhesive to affix the film to the backing sheet. Care should be taken when affixing the film to the backing sheet to leave as few film wrinkles as possible. If film wrinkles having a cumulative length of greater than about 2 cm are visible to the naked eye after affixation, that skin assembly should be discarded and a new skin assembly prepared.

In cases where an article of the invention contains a lotion or other skin care composition that transfers from the article to a portion of the wearer's skin as heretofore described (such as from a lotioned topsheet of a diaper), the skin assembly should be modified by applying a thin coating of the lotion or other skin care composition to the skin assembly to simulate a transfer of such a composition to a wearer's skin as may occur *in vivo*. In cases where the lotion or other skin care

composition acts as a carrier for an additional composition, including an agent such as an FMA, this additional composition/agent should be combined with the lotion or skin care composition as it would be in the article before the thin coating is applied. Otherwise, the procedure to modify the skin assembly described in the immediately following paragraph need not be performed, and the next step will be the application of Fluorescing fecal Analog B to the skin assembly.

To modify a skin assembly 201 with a lotion or skin care composition, skin assembly 201 is first weighed to the nearest 0.0001 gram and this initial weight recorded. The skin assembly is then placed on a paper towel on a flat surface such as a table with the black backing sheet facing the towel. As shown in Figure 14, a template 207, made by cutting a 7.6 by 20.3 cm (3 by 8 inch) paper segment from the earlier described black background paper and then cutting a 5 by 13 cm (2 by 5 inch) rectangular opening in the center of the paper segment, is centered and placed on the BIOCLUSIVE film 203 of skin assembly 201. A thin layer 209 of the lotion or other skin care composition (combined with an added composition/agent if the lotion or other skin care composition acts as a carrier for the added composition/agent) is deposited on the portion of the BIOCLUSIVE film 203 of skin assembly 201 which is exposed through the opening in template 207 so as to produce an substantially uniform lotion or other skin care composition layer covering substantially the entire exposed portion of the film. Such a thin layer may be deposited, for example, by rubbing a sample of the lotion or other skin care composition with the fingertips, and then rubbing the fingertips on the exposed portion of the BIOCLUSIVE film. Template 207 is removed and the modified skin assembly with the lotion or other skin care composition applied is weighed. The difference between modified skin assembly weight the initial weight represents the amount of lotion or other skin care composition present on the skin assembly. If this amount is below 0.0045 grams, then template 207 should again be placed on the skin assembly as previously described, additional lotion or other skin care composition applied, and the modified skin assembly reweighed until the amount is between 0.0045 grams and 0.0065 grams. If the amount exceeds 0.0065 grams, the skin assembly should be discarded and the aforesaid procedure recommenced until an assembly having an amount of

lotion or other skin care composition falling within the specified range is obtained. The skin assembly 201 is then stored in an incubator (e.g., Labeline Model 120, available from Labeline Instruments Inc. of Melrose Park, Illinois) at 38-39 degrees centigrade for one hour, in a manner which does not allow lotion to transfer from the assembly, to bring the assembly to human body temperature. This may decrease the viscosity of the lotion or other skin care composition, and allow formation of a more even layer of lotion or other composition on the BIOCLUSIVE film. Prior to application of a fluorescing fecal analog, as described below, skin assembly 201 is removed from the incubator.

As shown in Figure 15, Fluorescing Analog B (described above) 211 is disposed on a portion of the exposed BIOCLUSIVE film 203 (which may include the thin layer 209 described in the preceding paragraph) of skin assembly 201 using a REPLICA R120 self-adhesive locating ring 213 available from CuDerm Corp. of Dallas, Texas. With its release paper removed, locating ring 213 is placed adhesive side down on the exposed BIOCLUSIVE film 203 of skin assembly 201 with the outer edge of the ring tangentially aligned with an exposed transverse edge 215 of the film. Using a wood or metal spatula, the interior of locating ring 213 is overfilled with Fluorescing Analog B. Excess analog is scraped off to level the analog with the top of locating ring 213, taking care not to deposit any of the analog on the film outside the interior of the ring. Locating ring 213 is carefully removed from the skin assembly, leaving a level column of Fluorescing Analog B 211 approximately 19 mm in diameter and 1.1 mm in height.

In cases where an article of the invention contains a composition, including an agent such as an FMA, which is capable of transferring to the wearer's skin or bodily waste through means independent of any lotion or other skin care composition carrier, then the procedure described in the immediately following paragraph to add such a composition/agent to the skin assembly 201 prepared with Fluorescing Analog B 211 described above should be performed. If such an independent composition and/or agent is not present, the procedure described in the immediately following paragraph should not be performed, and the next step will be the performance of the wiping test.

To add a composition such as an FMA to skin assembly 201, the skin assembly is placed on a paper towel on a flat surface such as a table with black backing sheet 205 facing the towel. An agent template 217, made by cutting a 15.2 by 20.3 cm (6 by 8 inch) paper segment from the black background paper described above and then cutting a 5 by 13 cm (2 by 5 inch) rectangular opening in the center of the paper segment, is centered and placed on the BIOCLUSIVE film 203 of skin assembly 201. A mass of 0.5 grams of the composition/agent, shown as element 219 in Figure 16, is substantially uniformly distributed onto the portion of the BIOCLUSIVE film of skin assembly 201 which is exposed through the opening in agent template 217, as well as onto Fluorescing Analog B 211, so as to cover substantially the entire exposed portion of the film and fluorescing analog. Depending on the form of the composition/agent, the composition/agent may be uniformly distributed using any appropriate means known to one skilled in the art. For example, and without limitation, compositions/agents that are in powder form may be sifted onto the film through a strainer; those having a liquid form may be sprayed onto the film; and those having a higher viscosity may be manually rubbed onto the film as described above in connection with lotions or other skin care compositions. After distribution of the composition/agent, the agent template 217 is carefully removed.

Although the foregoing procedure is described in connection with the preparation of a single skin assembly, it should be understood that the procedures can be repeated to prepare additional skin assemblies. As described below, at least six assemblies of the same composition should be prepared and analyzed to ensure that reliable data has been obtained.

Wiping Test

As soon as an appropriate skin assembly or assemblies are prepared as described above, the skin assemblies are subjected to a wiping test. The wiping test utilizes a wiping sled 221, as shown in Figures 17-19. Sled 221 has a flat bottom surface 223 having a transverse dimension T of 12.7 cm (5 inches), and side edges 225 having a longitudinal dimension L extending 12.7 cm (5 inches). As shown in

Figure 17, the front 227 of sled 221 curves upwardly from flat bottom surface 223, the curve having a radius of 1.6 cm (0.62 inches) and extending from sled side edge to side edge. As shown in Figure 18, the front 227 of sled 221 also includes a transversely-extending concavity 229 having a radius of 12.7 cm (5 inches). Sled 221 may be made of aluminum or other suitable material so that the flat bottom surface of the sled (when the sled includes a clamping bar and wipe described below) applies a substantially uniform downward pressure of 0.324 kPa (0.047 psi) when placed on a flat horizontal surface such as a table top. As will be recognized by one skilled in the art, a weight or weights can be appropriately added to sled 221 so that the specified uniform pressure is applied. A pull line 231 is attached to a harness 233 attached to each side edge of 225 of sled 221. Pull line 231 extends to any suitable pulling apparatus 235 (such as a motorized drive that winds the pull line) capable of pulling sled 221 (along with the wipe described below) linearly over skin assembly 201 at a substantially constant speed of 17 cm per second.

The wiping test also utilizes a fresh wipe provided from a package of PAMPERS BABY FRESH wipes (unscented, alcohol free, with moisture pillows; available from The Procter & Gamble Company, Cincinnati, Ohio) or an equivalent wipe. A method of making such a PAMPERS BABY FRESH wipe is disclosed, modified as described below, in the Example set forth in U.S. Application Serial No. 08/915,349 entitled "Disposable Premoistened Wipe Having Opacity Agent", filed August 22, 1997 in the name of Gorely, which application is incorporated herein by reference. The Example in the aforesaid application is modified to make the PAMPERS BABY FRESH wipe referenced above by including about 76.4 percent cellulosic fibers, 12.9 percent polyester fibers, and 10.7 percent adhesive binder (the binder contains no titanium dioxide) in the substrate web. The web is embossed using the pattern described below, with an embossing roll having a land area of about 18 percent. The amount of binder adhesive sprayed on the web is sufficient to provide a dry web having about 10.7 percent by dry weight binder adhesive solids. As indicated in the aforesaid Example, the web is premoistened with a liquid composition comprising about 97% water, with the remaining 3% being the other listed minor constituents. The embossing pattern for the PAMPERS BABY FRESH

wipe is depicted in U.S. Design Patent No. 400,716, issued November 10, 1998, which is also incorporated herein by reference, the wipe having an embossing pattern repeat of 16.0 cm (6.3 inches), the character line thickness being 0.081 cm (0.032 inches), and the ellipses having a major diameter of 0.28 cm (0.11 inches) and minor diameter of 0.14 cm (0.055 inches).

The wipe described above is cut along its longitudinal axis into a wipe segment 237 approximately 10.8 cm wide by 17.8 cm long (4.25 by 7 inches). As shown in Figure 19, wipe segment 237 is affixed to sled 221 using a transversely-extending plastic clamping bar 239 (which may be held in place by set screws 240) so that the wipe segment is centered transversely on sled 221 and extends from clamping bar 239 to terminate at the sled rear edge 241.

As further shown in Figure 19, skin assembly 201 is attached to flat horizontal surface 243, such as a table top, with the backing paper facing down and centered in front of sled 221. The end of the skin assembly on which Fluorescing Analog B 211 is disposed is oriented toward the front 227 of sled 221, and the transverse edges of the skin assembly are oriented perpendicular to the direction in which the sled will be pulled. Prior to the sled pull described below, the distance between the sled front 227 and the Analog 211 should not exceed about 15 cm (5.9 inches) to ensure that wipe segment 237 does not lose excessive moisture during the pull, prior to contacting the Analog 211. The attachment of skin assembly 201 to flat surface 243 must be sufficient to prevent displacement of the skin assembly during the wiping test. Suitable attachment may be made using a piece of masking tape extending transversely over the edge of the skin assembly closest to sled 221 such that half of the tape width is firmly adhered to the backing and the remainder firmly adhered to the flat surface.

The wiping test is performed by employing pulling apparatus 235, pull line 231 and harness 233 to pull sled 221 and the affixed wipe segment 237 linearly over skin assembly 201 at a substantially constant speed of 17 cm per second, with the transverse centerline of sled 221 in alignment with the transverse centerline of the skin assembly 201 during the pull. Sled 221 is stopped after it clears the skin assembly. The wiped skin assembly is labeled appropriately, and placed aside to dry

for 8 hours at about 21 degrees centigrade and about 53 percent relative humidity before being analyzed using the image capture and analysis procedure described below.

Image Capture and Analysis Apparatus

The image capture and analysis apparatus includes a Sony 3-CCD model DXC-9000 progressive scanning color camera with an attached Fuji 7.5-105 mm zoom video lens model VCL714BCEA. The camera is mounted to a Beseler BECS-21 copy stand available from the Beseler Co. of Linden, New Jersey, with the lens facing downward and centered on a grid marked on the copy stand base. The video output from the camera is fed to both a VCR (video cassette recorder)/VCR monitor (e.g., Panasonic PV-M2048 VCR/monitor available from Panasonic Co., Secaucus, New Jersey) and to a video interface (Ultra II framegrabber available from CORECO of Quebec, Canada having a 2MB display controller and image buffer, and an RGB acquisition module) installed in an IBM-PC compatible computer system having an Intel 486 processor or higher. OPTIMAS version 6.21.19 Image Analysis software available from Media Cybernetics of Silver Springs, Maryland, and Microsoft EXCEL version 7.0a spreadsheet software available from Microsoft Corporation, Olympia, Washington, are also installed on the computer system.

The image capture and analysis apparatus also includes an ultraviolet (UV) light illumination system. The UV illumination system comprises two 35.6 cm (14 inch) F8T5 linear light fixtures (with the diffusers removed) with 25 kHz ballast from Stocker and Yale Inc. of Salem, New Hampshire, each fixture containing two Sylvania 8W BlacklightBlue FBW/BLB bulbs (peak wavelength 356 nm) and is attached to a frame. The frame is positioned on the copy stand base so that a skin assembly centered on the copy stand base grid will be centered transversely and longitudinally relative to the UV bulbs. The frame is constructed so as to position the bulbs approximately 10 cm (4 inches) above the copy stand base and to separate the light fixtures transversely from one another by approximately 20 cm (8 inches). Each light fixture is rotated around its major axis (at about a 45 degree angle) so that each fixture focuses the light toward the center of the copy stand base.

Camera Focusing and Brightness Calibration

A dried skin assembly containing the fluorescing fecal analog is used to provide a baseline image with which to set the camera focus and zoom. The skin assembly is centered on the copy stand grid, backing sheet down, under the activated UV lights, and the room is otherwise darkened. With the camera, computer and TV monitor on, the camera iris is opened to its maximum to yield a bright image. The camera is then focused and the lens zoom adjusted until the largest image of the BIOCLUSIVE film of the skin assembly can be seen on the VCR monitor and the computer screen, with the fluorescing portion in focus. The skin assembly is then removed. The camera focus and zoom will remain at these settings for the remainder of the image capturing session.

A UV calibration is then made to verify that the UV lights are providing the desired illumination. Using a Heavy Duty Ultraviolet Light Meter Model No. 40736A (UVA) (available from Extech Instruments of Waltham, Massachusetts), UV readings are taken at the center of the copy stand grid, and at two other locations on the grid which are each about 2.5 inches directly toward a respective light fixture from the grid center (i.e., one reading on each side of the center). If any of the readings are below about 0.25 milliwatts/cm², one or more of the UV bulbs must be changed.

Skin Assembly Image Capture

An ROI (region of interest) template 245, made by cutting a 7.6 by 20.3 cm (3 by 8 inch) paper segment from the earlier described black background paper and then cutting a 3 by 13 cm (1.2 by 5 inch) rectangular opening in the center of the paper segment, is provided as shown in Figure 20. White marks 247 are made on the template directly adjacent each corner of the rectangular opening so that the marks will appear in a captured image and be used to establish a consistently-sized ROI. Each skin assembly to be analyzed is centered on the copy stand grid, backing sheet down, with the UV illumination system activated. As also shown in Figure 20, the ROI template 245 is placed over the smear 251 of Fluorescing Analog B 211, with

the smear centered transversely in the rectangular opening and so that a transverse edge 253 of the rectangular opening is aligned with the edge 215 of the BIOCLUSIVE film (i.e., the edge adjacent to the earlier applied fluorescing fecal analog column). Using OPTIMAS, an image of this arrangement captured and saved as an appropriately identified TIFF file on the computer. The process is repeated for each skin assembly to be analyzed.

After images of all the skin assemblies are captured and saved, the UV illumination is turned off and the room once again illuminated normally. A ruler is placed on the copy stand in the center of the copy stand grid and an its image is captured and saved as the distance calibration reference image in an 8 bit TIFF RGB format (all images are saved in this TIFF format).

Image Analysis

Using OPTIMAS, the distance calibration reference image is opened to develop a distance calibration for the skin assembly images. Microsoft EXCEL is then run and a new spreadsheet opened. Returning to OPTIMAS, the Area Morphometry Data Collection Set is selected. The Set is edited if necessary by removing all of the measurements except mArArea (area in square calibrated units of a area object), and by adding the measurement mArGV (mean scaled luminance of pixels within an area boundary). Microsoft EXCEL is selected as the export data file and linked to the new spreadsheet called [Book1]Sheet1. In OPTIMAS, the desired skin assembly image file is then opened and a rectangular ROI is drawn to correspond to the rectangular opening of the ROI template appearing in the skin assembly image, using the ROI template reference marks as an aid for locating the corners of the rectangular opening. The blue channel is then selected which maximizes the contrast between the fluorescent analog smear and the background. The upper mean brightness threshold limit is set to 174. Then the area sampling parameters are adjusted by changing the minimum boundary length to 2, hole treatment to "ignore all holes", and boundaries to "on surrounding pixel center". The OPTIMAS software is then instructed to identify the areas of fluorescing fecal analog having a mean brightness exceeding the upper mean brightness threshold limit. The distance

calibration is then changed to the calibration based on the distance calibration reference image. OPTIMAS is then instructed to make mArArea and mArGV measurements from the skin assembly image, which are exported to the active spreadsheet [Book1]Sheet1. The measurement set spreadsheet is then named in Microsoft EXCEL consistently with the skin assembly measured, and the spreadsheet is saved on the computer. The foregoing process is repeated for each skin assembly image to be analyzed.

Calculations

The area of fluorescing fecal analog remaining on the skin assembly after wiping is determined from the measured value of each mArArea in cm^2 . Waste Contamination Area is calculated by summing all the mArArea values for the particular skin assembly analyzed, and then calculating the arithmetic mean of the sums obtained from the skin assemblies analyzed that are of the same composition. As described above, at least six skin assemblies should be analyzed.

The mass of fluorescing fecal analog remaining on the skin assembly after wiping is calculated from the equation $(\text{mArArea} \times \text{mArGV})/255$, where mArGV corresponds to the mean brightness of the pixels bounded by each area (i.e., the intensity of the fluorescence of the residual fecal analog remaining in each mArArea) and where the minimum brightness value is 0 and maximum is 255. In instances where the fecal analog remaining in an area has more than a certain thickness, a brightness value of 255 will always be measured and it is recognized that the mass of a thick area of remaining analog will be calculated as less than actual. Waste Contamination Mass, which is expressed in mass units, is calculated by summing all the $(\text{mArArea} \times \text{mArGV})/255$ values for the particular skin assembly analyzed, and then calculating the arithmetic mean of the sums obtained from the skin assemblies analyzed that are of the same composition.

Below is a sample table of OPTIMAS measurements obtained from analyzing a particular skin assembly, in an EXCEL spreadsheet with calculation columns.

Area Label	mArArea	mArGV	(mArArea X mArGV)/255
L0:	0.03	213.4	0.03
L1:	3.00	244.7	2.88
L2:	0.02	226.7	0.02
L3:	0.00	175.3	0.00
L4:	0.01	175.9	0.00
L5:	0.00	182.5	0.00
L6:	0.00	177.0	0.00
L7:	0.01	200.9	0.01
L8:	0.01	199.1	0.01
L9:	0.00	182.0	0.00
L10:	0.01	191.9	0.01
L11:	0.00	186.6	0.00
L12:	1.97	238.4	1.84
L13:	0.01	188.9	0.01
L14:	0.01	202.7	0.01
L15:	0.01	195.3	0.00
L16:	0.02	219.4	0.01
L17:	0.04	221.2	0.04
L18:	0.00	176.5	0.00
L19:	0.01	205.9	0.01
L20:	0.01	193.3	0.00
L21:	0.01	211.5	0.01
L22:	0.00	178.0	0.00
L23:	0.00	188.3	0.00
L24:	0.01	213.2	0.01
L25:	0.39	188.5	0.29
L26:	0.02	181.5	0.01
L27:	0.03	182.9	0.02
L28:	0.02	220.1	0.01
$\sum_{L0}^{Ln} mArArea = 5.65$		$\sum_{L0}^{Ln} (mArArea \times mArGV)/255 = 5.24$	

Waste Contamination Area = mean of $\sum_{L0}^{Ln} mArArea$ for $n \geq 6$ assemblies

Waste Contamination Mass = mean of $\sum_{L0}^{Ln} (mArArea \times mArGV)/255$ for $n \geq 6$ assemblies

5

While particular embodiments and/or individual features of the present invention have been illustrated and described, it would be obvious to those skilled in

the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. Further, it should be apparent that all combinations of such embodiments and features are possible and can result in preferred executions of the invention. Therefore, the appended claims are intended
5 to cover all such changes and modifications that are within the scope of this invention.

WHAT IS CLAIMED IS:

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

1. An absorbent article having a first waist region, a second waist region opposed to the first waist region, a crotch region disposed between the first waist region and the second waist region, the absorbent article comprising:
a topsheet;
5 a backsheet joined to at least a portion of the topsheet;
an absorbent core disposed between at least a portion of the topsheet and the backsheet, and
an effective amount of a feces modifying agent.
- 10 2. The absorbent article of Claim 1 wherein the feces modifying agent is a viscosity decreasing agent.
3. The absorbent article of Claim 1 wherein the feces modifying agent is a feces water-liberating agent.
- 15 4. The absorbent article of Claim 3 wherein the feces water liberating agent is a flocculant.
5. The absorbent article of Claim 3 wherein the feces water liberating agent includes an inorganic flocculant.
- 20 6. The absorbent article of Claim 5 wherein the inorganic flocculant is selected from the group including divalent and trivalent metal salts.
- 25 7. The absorbent article of Claim 6 wherein the metal salts are selected from the group consisting of: iron, aluminum, calcium, and sodium salts and mixtures thereof.
8. The absorbent article of Claim 6 wherein the metal salts are selected from the group consisting of: ferrous chloride, ferric chloride, aluminum potassium
- 30

sulfate, aluminum sulfate, sodium aluminate, ferrous sulfate, aluminum chloride hydroxide, and poly aluminum silicate sulfate.

9. The absorbent article of Claim 3 wherein the feces water liberating agent includes an organic flocculant.
10. The absorbent article of Claim 9 wherein the organic flocculant is selected from the group consisting of: water soluble polyamides and derivatives, polyacrylics and derivatives, polyamines, and polyvinylpyrrolidone.
11. The absorbent article of Claim 1 wherein the feces modifying agent includes a viscosity increasing agent.
12. The absorbent article of Claim 11 wherein the viscosity increasing agent includes a thickener.
13. The absorbent article of Claim 12 wherein the thickener is selected from the group including: carboxymethyl cellulose, xanthan gum, polyacrylic acid and salts thereof, polyacrylamide, and polyethyleneimines.
14. The absorbent article of Claim 11 wherein the viscosity increasing agent includes an ionic complexing agent.
15. The absorbent article of Claim 14 wherein the ionic complexing agent is selected from the group consisting of: ZnO, MgO, MnO, CaO, calcium hydroxide, ethanolamines, quaternary ammonium salts, and Al₂O₃, alginates, zinc salts, aluminum salts and combinations thereof.
16. The absorbent article of Claim 14 wherein the ionic complexing agent includes a crosslinking agent.

17. The absorbent article of Claim 1 wherein the feces modifying agent reduces the Hardness of the feces by at least about 25% at a concentration of no more than about 0.5 weight percent.
- 5 18. The absorbent article of Claim 1 wherein the feces modifying agent increases the Hardness of the feces by greater than or equal to about 100% at a concentration of no more than about 0.5 weight percent.
- 10 19. The absorbent article of Claim 1 wherein the feces modifying agent is present in concentration of greater than or equal to about 0.01% by weight of the article.
- 15 20. The absorbent article of Claim 1 further including at least one three-dimensional structure joined to or extending from an element of the absorbent article, the three-dimensional structure comprising a feces modifying agent, wherein the three-dimensional structure promotes contact between the agent and the feces.
- 20 21. The absorbent article of Claim 20 wherein at least some of the three-dimensional structures are selected from the group consisting of loop structures, and structures comprising printed hairs.
- 25 22. An absorbent article having a first waist region, a second waist region opposed to the first waist region, a crotch region disposed between the first waist region and the second waist region, the absorbent article comprising:
a liquid pervious topsheet;
a liquid impervious backsheet joined to at least a portion of the topsheet;
an absorbent core disposed between at least a portion of the topsheet and the backsheet,

a waste management element having an Acceptance Under Pressure value of greater than about 0.50 grams of a viscous fluid bodily waste per square inch of the waste management element per milliJoule of energy input, and an effective concentration of a feces modifying agent.

5

23. An insert to be placed in a wearer's garment, the insert comprising:
a first end region;
a second end region opposed to said first end region;
a central region separating said first end region and said second end region,
and
an effective amount of a feces modifying agent.

10

15

24. The insert of Claim 23 wherein the feces modifying agent is a viscosity decreasing agent.
25. The insert of Claim 23 wherein the feces modifying agent is a feces water-liberating agent.
26. The insert of Claim 23 wherein the feces modifying agent includes a viscosity increasing agent.

20

25

27. The insert of Claim 23 further including at least one three-dimensional structure joined to or extending from an element of the insert, the three-dimensional structure comprising a feces modifying agent, wherein the three-dimensional structure promotes contact between the agent and the feces.
28. A disposable article adapted to be worn by a wearer comprising:
one or more compositions for enhancing the removability of fecal waste from the skin of the wearer, said one or more compositions being available to at least a portion of one of said fecal waste and said skin of said wearer;

30

wherein said one or more compositions provide one or more of the following as determined by the test methods set forth in the specification:

- a) a Waste Contamination Area of less than about 15 cm²;
- b) a Waste Contamination Mass of less than about 14 mass units.

5

29. The disposable article of Claim 28 wherein said one or more compositions provide a Waste Contamination Area of less than about 12 cm².

10

30. The disposable article of Claim 29 wherein said one or more compositions provide a Waste Contamination Area of less than about 10 cm².

31. The disposable article of Claim 29 wherein said one or more compositions provide a Waste Contamination Mass of less than about 10 mass units.

15

32. The disposable article of Claim 31 wherein said one or more compositions provide a Waste Contamination Mass of less than about 8 mass units.

20

33. The disposable article of Claim 31 wherein said one or more compositions provide a Waste Contamination Area of less than about 12 cm² and a Waste Contamination Mass of less than about 10 mass units.

34. The disposable article of Claim 28 wherein at least one of said compositions comprises an effective amount of a feces modifying agent.

25

35. The disposable article of Claim 34 wherein at least one of said compositions comprises a skin care composition.

36. The disposable article of Claim 28 comprising a skin care composition on a wearer-contacting surface.

30

37. The disposable article of Claims 35 or 36 wherein said skin care composition comprises a material selected from the group consisting of: a petroleum oils, petroleum waxes, silicone oils, and silicone waxes.
- 5 38. The absorbent article of Claim 34 wherein the feces modifying agent is a viscosity decreasing agent.
39. The absorbent article of Claim 34 wherein the feces modifying agent is a feces water-liberating agent.
- 10 40. The absorbent article of Claim 34 wherein the feces modifying agent includes a viscosity increasing agent.
41. The absorbent article of Claim 40 wherein the viscosity increasing agent includes a thickener.
- 15 42. The absorbent article of Claim 41 wherein the thickener is selected from the group including: carboxymethyl cellulose, xanthan gum, polyacrylic acid and salts thereof, polyacrylamide, and polyethyleneimines.
- 20 43. The absorbent article of Claim 40 wherein the viscosity increasing agent includes an ionic complexing agent.
44. The absorbent article of Claim 43 wherein the ionic complexing agent is selected from the group consisting of: ZnO, MgO, MnO, CaO, calcium hydroxide, ethanolamines, quaternary ammonium salts, Al₂O₃, alginates, zinc salts, aluminum salts and combinations thereof.
- 25 45. The absorbent article of Claim 34 wherein the feces modifying agent reduces the Hardness of the feces by at least about 25% at a concentration of no more than about 0.5 weight percent.
- 30

46. The absorbent article of Claim 34 wherein the feces modifying agent increases the Hardness of the feces by greater than or equal to about 100% at a concentration of no more than about 0.5 weight percent.
- 5
47. The disposable article of claim 34 wherein said feces modifying agent is disposed in the article as an individual discrete element.
48. The disposable article of Claim 34 wherein said feces modifying agent is associated with a carrier structure which includes a component selected from the group consisting of: a web of material, a film, a fibrous structure, a loop material, a brush structure, and a structure which releasably encapsulates said feces modifying agent.
- 10
49. The disposable article of Claim 28 further comprising a responsive system including a sensor operatively connected to the article, the sensor adapted to detect an input, and an actuator operatively connected to the article, the actuator being adapted to deliver said one or more compositions to at least a portion of said fecal waste excreted from said wearer when the sensor detects the input.
- 15
50. A disposable article for receiving bodily waste from a wearer, the disposable article including:
a bag including an opening,
means for joining the bag to the wearer,
an effective amount of a feces modifying agent.
- 20
51. The disposable article of Claim 50 wherein the feces modifying agent is a viscosity decreasing agent.
- 25
- 30

52. The disposable article of Claim 50 wherein the feces modifying agent is a feces water-liberating agent.
53. The disposable article of Claim 50 wherein the feces modifying agent is a calcium-based modifying agent.
54. The disposable article of Claim 50 wherein the feces modifying agent includes a viscosity increasing agent.
55. The disposable article of Claim 50 wherein the feces modifying agent reduces the Hardness of the feces by at least about 25% at a concentration of no more than about 0.5 weight percent.
56. The disposable article of Claim 50, wherein the article is selected from the group of a colostomy bag or a waste bag.
57. The disposable article of Claim 50, wherein the joining means comprises a body compatible pressure sensitive adhesive.
58. A method of enhancing the removability of bodily waste from the skin of a wearer of a disposable article, the method comprising:
providing a disposable article adapted to be worn by the wearer;
associating one or more compositions for enhancing the removability of fecal waste from the skin of the wearer with said disposable article so that said one or more compositions are available to at least a portion of one of said bodily waste and said skin of said wearer;
said one or more compositions providing one or more of the following as determined by the test methods set forth in the specification:
a) a Waste Contamination Area of less than about 15 cm²;
b) a Waste Contamination Mass of less than about 14 mass units.

59. The method of Claim 58 wherein at least one of said compositions comprises an effective amount of a feces modifying agent.
60. The disposable article of Claim 59 wherein at least one of said compositions comprises a skin care composition.
- 5

5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

DISPOSABLE ARTICLE PROVIDING
IMPROVED MANAGEMENT OF BODILY EXUDATES

5

ABSTRACT

A disposable article adapted to receive bodily exudates which provides improved management of such bodily exudates by including an effective amount of one or more agents which act to modify the physical properties of feces or other bodily wastes which may be deposited in the article, or by including one or more compositions such as the aforesaid one or more agents which enhance the
10 removability of bodily waste, such as feces, from the skin of the article's wearer.




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6





Fig. 7



6/15




Fig. 9




Fig. 10




Fig. 11




Fig. 12




Fig. 13




Fig. 14

10/15




Fig. 15




Fig. 16




Fig. 17




Fig. 18




Fig. 19




Fig. 20




Fig. 21




Fig. 22

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **DISPOSABLE ARTICLE PROVIDING IMPROVED MANAGEMENT OF BODILY EXUDATES** the specification of which

(check one) ☒ [X] is attached hereto.
☐ [] was filed on _____ as
 Application Serial No. _____
 and was amended on _____
 (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in accordance with Title 37 Code of Federal Regulations §1.56.

I hereby claim foreign priority benefits under Title 35 United States Code §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or Inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed

(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
----------	-----------	------------------------	------------------------------	-----------------------------

I hereby claim the benefit under Title 35 United States Code §119(e) and §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35 United States Code §112, I acknowledge the duty to disclose material information as defined in Title 37 Code of Federal Regulations §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>60/091,076</u>	<u>6/29/98</u>	<u>Pending</u>
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
<u>09/107,561</u>	<u>6/29/98</u>	<u>Pending</u>
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
<u>09/106,225</u>	<u>6/29/98</u>	<u>Pending</u>
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
<u>60/090,993</u>	<u>6/29/98</u>	<u>Pending</u>
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
<u>08/970,508</u>	<u>11/14/97</u>	<u>Allowed</u>
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

I hereby appoint the following as my attorney(s) or agent(s) with full power of substitution to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

<u>Atty Name</u>	<u>Atty Reg Number</u>	<u>Associate Power of Attorney Attached</u>
Kevin D. Hogg	31,839	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
David M. Weirich	38,361	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Thomas J. Osborne	39,796	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Steven W. Miller	31,984	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
E. Kelly Linman	26,759	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Jacobus C. Rasser	37,043	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
T. David Reed (Agent)	32,931	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Timothy B. Guffey (Agent)	41,048	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SEND CORRESPONDENCE TO:

Kevin D. Hogg
 The Procter & Gamble Company (513) 634-1331
 Winton Hill Technical Center
 6300 Center Hill Avenue
 Cincinnati, Ohio 45224

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first joint inventor DONALD C. ROE

Inventor's signature _____

_____ Date

Residence 6324 Emberwood Court, West Chester, Ohio 45069

Citizenship USA

Post Office Address The Procter & Gamble Company, Winton Hill Technical Center
6110 Center Hill Avenue, Cincinnati, Ohio 45224

Full name of second joint inventor, if any NICHOLAS A. AHR

Inventor's signature _____

_____ Date

Residence 3736 Benhill Drive, Cincinnati, Ohio 45247

Citizenship USA

Post Office Address The Procter & Gamble Company, Winton Hill Technical Center
6110 Center Hill Avenue, Cincinnati, Ohio 45224

Full name of third joint inventor, if any CHRISTOPHER P. BEWICK-SONNTAG

Inventor's signature _____

_____ Date

Residence Via Giorgione n.9, 65125 Pescara, Italy

Citizenship Australian/British

Post Office Address The Procter & Gamble Company, Winton Hill Technical Center
6110 Center Hill Avenue, Cincinnati, Ohio 45224

Full name of fourth joint inventor, if any MATTIAS (NMN) SCHMIDT

Inventor's signature _____

_____ Date

Residence Altkenigweg 3, 65510 Idstein, Germany

Citizenship German

Post Office Address The Procter & Gamble Company, Winton Hill Technical Center
6110 Center Hill Avenue, Cincinnati, Ohio 45224

Full name of fifth joint inventor, if any OLIVER E. C. MASON

Inventor's signature _____

_____ Date

Residence 9849 Coventry Ct., Mason, Ohio 45040

Citizenship United Kingdom

Post Office Address The Procter & Gamble Company, Winton Hill Technical Center
6110 Center Hill Avenue, Cincinnati, Ohio 45224

Full name of sixth joint inventor, if any STEPHEN A. GOLDMAN

Inventor's signature _____

_____ Date

Residence Via Calli di Moro 62, 65013 Citta S. Angelo, Pescara, Italy

Citizenship USA

Post Office Address The Procter & Gamble Company, Winton Hill Technical Center
6110 Center Hill Avenue, Cincinnati, Ohio 45224